Targeting mutant KRAS in pancreatic cancer by Hayes, Tikvah
	 
 
 
 
 
 
TARGETING MUTANT KRAS IN PANCREATIC CANCER 
 
 
 
 
Tikvah Katheryn Hayes 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in the Curriculum in 
Genetics and Molecular Biology.  
 
 
 
 
 
Chapel Hill 
2015 
 
                        Approved by: 
 
Albert S. Baldwin 
 
Christopher M. Counter 
 
Channing J. Der 
 
Gary L. Johnson 
 
William Y. Kim 
 
 
 
 
	 ii	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
Tikvah Katheryn Hayes 
ALL RIGHTS RESERVED 
  
	 iii	
 
 
 
 
 
 
ABSTRACT 
 
Tikvah Katheryn Hayes: Targeting mutant KRAS in pancreatic cancer 
(Under the direction of Channing Der) 
 
The development of pharmacologic inhibitors of the KRAS oncoprotein, which is mutated 
in ~30% of all human cancers, has been at the forefront of drug discovery for the last three 
decades.  Despite intensive efforts by the pharmaceutical industry, no effective anti-KRAS 
strategies have reached the cancer patient.  While many approaches to achieve this are being 
pursued, arguably inhibition of mutant KRAS effector signaling is considered the most promising 
to block KRAS-driven cancer growth.  The best-validated downstream effector of KRAS is a three-
tiered protein kinase cascade, the Raf-MEK-ERK protein kinase cascade, where KRAS activates 
Raf, which then activates MEK, and MEK then activates ERK.  Activated ERK then activates a 
complex spectrum of signaling events that then drive cancer growth.  Unfortunately, inhibitors of 
the first two levels, targeting Raf or MEK, have proven ineffective in mutant KRAS cancers.  The 
ineffectiveness of anti-Raf and –MEK therapies has been attributed to inhibitor-induced resistance 
mechanisms, where the majority cause reactivation of ERK signaling to bypass the action of these 
inhibitors.  Our studies sought to determine whether pharmacological inhibition of the last step at 
ERK will be more efficacious than treatment with either MEK or Raf inhibitors in mutant KRAS 
cancers.   
In our studies, we first determined that pharmacologic inhibition of ERK suppressed the growth of 
a subset of KRAS-mutant pancreatic cancer cell lines by inducing both cycle cell arrest and 
apoptosis.  Interestingly, we found that concurrent PI3K inhibition, another well-established KRAS 
effector, modulated ERK inhibitor sensitivity by enhancing the apoptotic phenotype.  Next, we 
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employed a drug sensitivity screen to identify novel inhibitor combinations that enhanced ERK 
inhibitor sensitivity.  We identified the PI3K-AKT-mTOR signaling cascade as a potent modulator 
of ERK inhibitor sensitivity, which was consistent with our previous finding where concurrent PI3K 
inhibition combination enhanced ERK inhibitor sensitivity.  We unexpectedly found that long-term 
treatment of sensitive cell lines caused cellular senescence, a type of irreversible growth arrest, 
mediated in part by causing degradation of Myc and activation of the p16-RB tumor suppressor 
pathway.  Next, we performed a novel genetic gain-of-function screen to identify mechanisms of 
acquired resistance to ERK inhibition.  Interestingly, we identified, once again, the PI3K-AKT 
signaling cascade, as modulator of ERK inhibitor sensitivity.  We also found p38 to be an important 
modulator or ERK inhibitor sensitivity.  Finally, to investigate de novo resistance to ERK inhibition, 
we used a loss-of-function screen to identify kinases whose inhibition in combination with ERK 
inhibitor treatment resulted in sensitivity.  Future studies will be needed to elucidate the 
mechanisms behind these modulators of pharmacological ERK inhibition.  Collectively, our 
findings not only revealed distinct consequences of inhibiting this kinase cascade at the level of 
ERK, but identified inhibitor combinations that will be informative for potential clinical trials. 
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CHAPTER 1: INTRODUCTION 
 
1.1 RAS genes and Ras proteins 
 
The three human RAS genes encode four highly related 188-189 amino acid 21 kDa small 
GTPases (Figure 1.1).  K-Ras4A and K-Ras4B are splice variants encoded by alternative exon 4 
usage and differ primarily at their C-terminal sequences.  The RAS genes comprise one the most 
frequently mutated gene family in human cancer (Cox and Der, 2010). In cancer and various 
developmental disorders (referred to as Rasolopaties), RAS genes harbor missense mutations 
that encode mutant proteins that are altered in their biochemical properties (Prior et al., 2012; 
Rauen, 2013).  
Ras proteins act as binary switches regulating a number of biological processes that 
include cellular proliferation, survival and differentiation.  Ras proteins share 90% sequence 
identity in the G domain (1-164), which is important for guanine nucleotide binding and GTP 
hydrolysis, and interaction with regulators and effectors. In contrast, the C-terminal 24/25 residues 
exhibit significant sequence divergence (8% amino acid identity) and is therefore referred to as 
the hypervariable region (HVR).   
Ras activity is regulated by two distinct classes of regulatory proteins: Ras-selective 
guanine exchange factors (RasGEFs) and GTPases activating proteins (RasGAPs) (Figure 1.2) 
(Vigil et al., 2010).  RasGEFs (e.g., Sos1) accelerate the slow intrinsic guanine nucleotide 
exchange rate of Ras proteins. Since the intracellular concentration of GTP is 10 times more 
abundant than GDP, this favors formation of the active Ras-GTP complex.  Once bound to GTP, 
Ras is considered activated and can bind to a number of catalytically distinct downstream 
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effectors to regulate a diversity of cytoplasmic signaling networks.  In order to terminate Ras 
signal transduction, RasGAPs (e.g., neurofibromin, p120 RasGAP) bind to Ras and accelerate 
its weak intrinsic GTP hydrolysis activity, returning Ras to the inactive GDP-bound form.  
However, when Ras proteins are mutated, they display altered intrinsic and GAP-stimulated 
GTPase activity, favoring a GTP-bound state and promotion of aberrant signal transduction. 
The C-terminal sequence is crucial for Ras membrane association and subcellular 
localization (Figure 1.3). The terminal four residues comprise the CAAX motif (C = cyteine, A = 
aliphatic amino acid, X = terminal amino acid), which signals for three sequential posttranslational 
modifications that increase hydrophobicity and promote membrane association (Ahearn et al., 
2012).  The sequences immediately upstream of the CAAX motif contain a second membrane 
targeting signal.  For H-Ras, K-Ras4A and N-Ras, cysteine residues signal for covalent addition 
of a palmitate fatty acid, whereas K-Ras4B has a polybasic stretch that serves a similar role. K-
Ras4B additionally contains a serine residue (S181) that is phosphorylated by protein kinase C.  
This modification regulates a dynamic trafficking between the plasma and endomembranes. In 
addition to association with the plasma membrane, Ras proteins are also found in other cellular 
endomembrane compartments that include the Golgi, endoplasmic reticulum, mitochondria, and 
endosomes. 
1.2 Ras and cancer  
 
In 1982, the RAS genes became the first mutated genes identified in human cancers (Cox 
and Der, 2010).  In this chapter we discuss the role of RAS gene mutations in cancer. In particular, 
we focus on the RAS gene most commonly mutated in human cancers, the KRAS oncogene 
(Prior et al., 2012).  Although KRAS mutations are found in many cancer types, the highest 
frequency is found in pancreatic ductal adenocarcinoma (PDAC) at ~95% (Bass et al., 2011; 
Biankin et al., 2012; Jones et al., 2008; Seshagiri et al., 2012; Wood et al., 2007).   
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PDAC is the fourth leading cancer related death in the United States (Siegel et al., 2014).  
Among 45,220 individuals diagnosed with PDAC in 2014, approximately 38,000 died of the 
disease (Siegel et al., 2014).  While the mortality rate for most cancers is declining, PDAC is 
projected to become the second most common cause of cancer-related death by 2020.  Given 
the vague clinical symptoms and the lack of effective screening methods, only 10-20% of PDAC 
patients are candidates for curative resection at the time of diagnosis. Even with surgical resection 
followed by adjuvant therapy, the median overall survival of those patients is around two years 
(Conroy et al., 2011; Neoptolemos et al., 2010; Oettle et al., 2007).  Among the rest of the PDAC 
patients who are not candidates for resection, half of them have localized disease (borderline 
resectable and locally-advanced disease) and half have metastatic disease at the time of 
diagnosis.  Patients with local disease are most often treated with chemotherapy with or without 
radiation, and their median overall survivals are around 15 months (Huguet et al., 2007).  In 
patients with metastatic PDAC, the prognosis is extremely dismal. With the recent development 
of chemotherapy regimens such as FOLFIRINOX (Conroy et al., 2011) and gemcitabine plus nab-
paclitaxel (Von Hoff et al., 2013), the survival of metastatic PDAC has moved beyond 6 months 
(Burris et al., 1997), but remains less than one year.  At present, targeted therapies have not 
provided any meaningful clinical benefit for PDAC patients despite the approval of the EGFR 
inhibitor erlotinib (Moore et al., 2007).  The poor prognosis associated with PDAC reflects an 
urgent need for novel drug development.  
1.3 RAS mutations are early events in cancer development and progression 
 
 Ras mutations are generally early events in cancer development and progression (Figure 
1.4).  For pancreatic cancer, KRAS mutations are the initiating genetic event, followed by a 
progression of mutations in three tumor suppressor genes.  The early onset of RAS mutations in 
cancer emphasizes their key role in promoting the initiation and progression of cancer.  This role 
is supported by genetically engineered mouse model studies where tissue restricted Kras 
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mutational activation initiates the early stages of cancer development (Hingorani et al., 2003b). 
However, when coupled with additional mutations in tumor suppressors, Kras-initiated tumor 
formation was accelerated and advanced to invasive and metastatic disease. For example, Kras 
(G12D) activation alone induced ductal lesions that recapitulated the full spectrum of human 
pancreatic intraepithelial neoplasias (PanINs), the putative precursors to invasive pancreatic 
cancer (Hingorani et al., 2003b). At low frequency, these lesions also progressed to invasive and 
metastatic adenocarcinomas. However, when combined with a mutation in the Tp53 (R172H) 
tumor suppressor, rapid onset of invasive and widely metastatic carcinoma was seen (Hingorani 
et al., 2005).  Decreased latency and acceleration of metastatic PDAC was seen when mutational 
activation of Kras (G12D) was coupled with the deletion of either of the other two key tumor 
suppressor lesions in this cancer (CDKN2A/INK4A and SMAD4) (Bardeesy et al., 2006a; 
Bardeesy et al., 2006b; Waddell et al., 2015).   
Despite their clear role in tumor initiation and progression, continued expression of mutant 
KRAS is still required for maintenance of the primary and advanced metastatic cancer. For 
pancreatic cancer, this was first demonstrated by RNA interference suppression of mutant KRAS 
(G12V) expression in the KRAS mutant Capan-1 human PDAC cell line, causing loss of loss of 
anchorage-independent growth in vitro and impaired tumorigenic growth in vivo (Brummelkamp 
et al., 2002). Subsequently, it was shown that induction of RNAi suppression of KRAS in vivo 
impaired the growth of Capan-1 PDAC cell line xenograft tumors (Lim and Counter, 2005). 
Subsequent studies showed that shRNA suppression of KRAS expression impaired the growth 
of other KRAS mutant PDAC cell lines (Singh et al., 2009). More recently, two groups 
independently showed that continued mutant Kras G12D expression was required for the 
maintenance of PDAC growth in Kras G12D/Tp53 null mouse models of PDAC (Collins et al., 
2012a; Collins et al., 2012b; Ying et al., 2012). 
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1.4 RAS mutations in human cancers 
 
 Data in COSMIC shows that the RAS genes are mutated in 33% of all cancers evaluated, 
making it the most frequently mutated oncogene family in cancer 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). There are three common sites for 
Ras mutational activation, residues G12, G13, and Q61, which together account for >95% of 
identified mutations (Cox and Der, 2010). Mutational activation at G12 and G13 interferes with 
the ability of Ras to be stimulated by GAPs, as any other residue aside from glycine creates steric 
hindrance (Scheffzek et al., 1997).  However, mutational activation at Q61 disrupts the 
coordination of the water molecule necessary for GTP-hydrolysis (Scheidig et al., 1999). Once 
mutated at G12, G13, or Q61 Ras becomes constitutively active, leading to aberrant activation of 
downstream effectors.  Of the Ras isoforms, KRAS is the most frequently mutated accounting for 
~85% of all RAS mutations found in cancer (Cox and Der, 2010). 
The frequency of mutation of the three RAS genes varies significantly with KRAS is the 
most commonly mutated isoform. Mutation data available in COSMIC v68 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) shows that KRAS mutations were 
found in 29,557 of 139, 474 unique samples analyzed (21.2%), followed by NRAS, found in 3,587 
of 62,609 samples (5.7%), with HRAS mutations relatively rare, found in 1,127 of 35,366 samples 
(3.2%) (Table 1.1).  The simple summation of these data is the basis for the ~30% RAS mutation 
frequency found in all human cancers.  Mutation frequencies from other databases (e.g., 
cBioPortal; (http://www.cbioportal.org/public-portal/), representing a smaller dataset, although 
with more accurate data restricted to deep sequencing studies, come up with a reduced 
frequency.  Since the cancers represented in each database are different, no one source provides 
a truly accurate determination of the frequency of RAS mutations in cancer. 
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There is preferential mutation of a specific isoform in different cancers, with near exclusive 
mutation of KRAS in PDAC.  In contrast, NRAS is the predominant isoform mutated in melanoma 
and acute myelogenous leukemias, whereas HRAS is the predominant isoform mutated in 
bladder and head and neck squamous cell carcinomas. The majority of missense mutations found 
in RAS occur at G12, G13 and Q61. This pattern contrasts with RAS mutations found in 
developmental disorders.  There are also RAS isoform distinct frequencies in these mutations, 
with Q61 mutations rare in KRAS, yet the predominant mutation seen in NRAS. Finally, the 
mutation spectrum found in KRAS varies widely in different cancers.  For example, the G12C is 
the predominant mutation found in lung cancer, it is rarely seen in PDAC. 
1.5 Ras Effectors 
 
 There are at least 11 catalytically-distinct classes of Ras effectors (Vigil et al., 2010).  Ras 
effectors typically possess either a Ras binding (RBD) or Ras association (RA) domain that 
facilitates preferential binding to activated GTP-bound Ras.  Of these effector classes, six have 
been validated roles in Ras-mediated oncogenesis: Raf serine/threonine kinases, class I 
phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3K), and GEFs for the Ral (RalGEFs) and 
Rac1 (Tiam1) small GTPases (Figure 1.5) (Cox et al., 2014).  Of these, Raf and PI3K are the best 
validated, in part, because of their frequent mutational activation in human cancer (Davies et al., 
2002; Karakas et al., 2006).  In addition to their mutational prevalence in cancer, both Raf and 
PI3K possess catalytic activities that represent tractable drug targets. Furthermore, downstream 
components of both Raf and PI3K signaling cascades have been targeted for drug discovery with 
some success.  Taken together these findings have placed Raf and PI3K at the forefront of drug 
discovery as the two key downstream effectors of Ras.  
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1.6 The Raf-MEK-ERK kinase cascade 
 
The Raf-MEK-ERK three-tiered protein kinase cascade is one of three major MAPK kinase 
kinase (MAPKKK/MAP3K)- MAPK kinase (MAPKK/MAP2K)-MAPK modules involved in 
cytoplasmic signaling downstream of active cell surface receptors. The other two MAPKs, p38 
and JNK, have less significant roles in oncogenesis and are not known to be directly activated 
downstream of Ras.  Therefore, in this thesis, we focus on the Raf-MEK-ERK cascade in Ras 
signaling. 
1.6.1 Raf serine/threonine kinases 
 
 There are three distinct Raf (MAPKKK/MAP3K) isoforms: A-Raf, B-Raf, and Raf-1 (c-Raf).  
Like Ras isoforms, Raf isoforms share similar sequence identity and conserved domain topology 
(Figure 1.6).  The N-terminal region contains an RBD followed by a cysteine-rich domain 
(CRD/C1), while the C-terminal region contains the serine/threonine kinase domain.  Generally, 
N-Ras, H-Ras, and K-Ras activate Raf-1 and B-Raf similarly, whereas A-Raf is only weakly 
activated by Ras (Rodriguez-Viciana et al., 2004).  Ras-GTP binding to the RBD relieves the N-
terminal auto-inhibitory activity and additionally recruits Raf to the plasma membrane, where 
additional phosphorylation events and interactions facilitate activation of Raf catalytic function 
(Figure 1.7). How Ras causes activation of Raf is complex and still not completely understood, 
with most studies focused on Raf-1, the isoform found originally transduced and activated in the 
3611-MSV oncogenic retrovirus that caused rapidly accelerated fibrosarcomas (Matallanas et al., 
2011) 
 Inactive Raf-1 exists in a closed confirmation stabilized by the 14-3-3 complex interacting 
with residues S259 in the N-terminal region and S621 in the C-terminal region (Roskoski, 2010).  
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RTKs recruit the Sos1 RasGEF to the plasma membrane where it catalyzes the formation of Ras-
GTP (Figure 1.8).  PP1 and PP2A phosphatases dephosphorylate Raf-1 at residue S259 
permitting Ras-GTP to bind the Raf-1 RBD effectively resulting in an open yet inactive 
confirmation.  Several known (PAK, CK2, Raf, Src, and Jak) and unknown kinases phosphorylate 
the C-terminal region of Raf-1 at residues S338 and Y341.  Once activated, Raf proteins either 
homo- or heterodimerize, which is stabilized by either the 14-3-3 complex, KSR-1, or MLK-3, all 
well validated scaffolds.   
 Once Raf-1 is activated, it can phosphorylate its only known physiological downstream 
substrates, the closely related MEK1 and MEK2 dual specificity protein kinases.  Raf kinases 
phosphorylate MEK1 and MEK2 at two sites (S218 and S222), which are located in the activation 
loop.  Once active MEK1/2 phosphorylate ERK, which also has two distinct isoforms.  As a 
consequence, the field has relied heavily on changes to levels of phosphorylated ERK1 and ERK2 
to determine Ras-Raf signaling activation. 
 B-Raf activation is similar to Raf-1 activation, though several observations have suggested 
that B-Raf activation may require fewer components (Matallanas et al., 2011).  Currently, the 
model for B-Raf activation is thought to require Ras and 14-3-3 complex interactions for activation.  
Unlike Raf-1, B-Raf contains a negatively charged N-terminal domain due to the presence of both 
aspartate at the position corresponding to Raf-1 residue Y341 (D448/449) and constitutive 
phosphorylation of B-Raf at residue S446, which corresponds to Raf-1 S338.  Together these 
residues promote the stabilization of the 3-dimensional catalytic domain.  Like Raf-1, active B-Raf 
also phosphorylates the MEK1 and MEK2 kinases leading to ERK1 and ERK2 phosphorylation. 
 Of the Raf kinases, A-Raf is most poorly understood, as it is not mutated in cancer nor 
has it been identified as a resistance mechanism to any targeted therapies.  A-Raf association 
with mutated Ras is weak as a consequence of the presence of a lysine at position 22, located 
within the A-Raf RBD (Matallanas et al., 2011).  Consistent with this observation, A-Raf seems to 
be only weakly activated by Ras.  Furthermore, there are several non-conserved acidic amino 
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residues found in the N-terminal domain of A-Raf, most important being Y296, which if mutated 
results in a constitutively active kinase.  This residue, in particular, is thought to stabilize the N-
terminal domain interaction with the catalytic domain promoting a closed kinase confirmation.  In 
the C-terminal domain, residue S432, located between the ATP-binding motif and the activation 
loop, is crucial for both MEK activation and A-Raf signaling.  Unlike B-Raf, A-Raf contains a cluster 
of phosphorylation sites between residues 248 and 267, which, once activated, contribute to 
dissociation from the plasma membrane.  Thus, A-Raf signaling has been found at several 
subcellular compartments, including the Golgi apparatus, endosomes and mitochondria. 
1.6.2 MEK dual specificity kinases 
 
MEK1 and MEK2 (MAP/ERK kinase; MAPKK/MAP2K) are highly related dual specificity 
kinases that catalyze the phosphorylation of both threonine and tyrosine residues in the TxY motif 
their only known substrates, ERK1 and ERK2 (Roskoski, 2012b)(Figure 6). MEK1/2 structure can 
be split into three distinct functional domains: N-terminal domain, protein kinase domain, and a 
short C-terminal domain (Fischmann et al., 2009).  The N-terminal region consists of an inhibitory 
domain, a nuclear export domain, and a domain that aids in the ability to bind the ERK kinases. 
The kinase domain comprises the majority of MEK1/2 structure and includes the activation 
segment and the proline-rich segment.  Raf activates MEK1/2 by dual phosphorylation at tandem 
serine residues (Figure 1.6).  Two other known activators of MEK1/2 are the COT/Tpl2 and Mos 
serine/threonine kinases.  Like Raf, Tpl2 and Mos were also identified originally as retroviral 
oncogenes and act as MAPKKK/MAP3Ks (Moloney, 1966; Salmeron et al., 1996). The PAK1 
serine/threonine kinase can phosphorylate and modulate MEK1 at S298, promoting Raf activation 
of MEK (Coles and Shaw, 2002; Slack-Davis et al., 2003). 
1.6.3 ERK serine /threonine kinases 
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The only well-established MEK1 and MEK2 substrates are the highly related ERK1 and ERK2 
serine/threonine kinases (Figure 1.6).   Phosphorylation of the ERK kinases is the most common 
readout for Ras activation of the Raf-MEK-ERK signaling cascade (Roskoski, 2012a). Like many 
protein kinases ERK1 and ERK2 have short N-terminal and C-terminal domains, with the protein 
kinase domain making up the largest region.  All known cellular activators of ERK1 and ERK2 
lead to phosphorylation and activation of both kinases in parallel (Lefloch et al., 2009).  To become 
active MEK1/2 phosphorylate ERK1 and ERK2 at residues T202 and Y204, starting with the 
tyrosine residue.   
Whether ERK1 and ERK2 have unique biological functions has been under evaluation for the 
last decade.  There is evidence that genetic ablation of Erk2 but not Erk1 causes embryonic 
lethality (Hatano et al., 2003; Pages et al., 1999; Saba-El-Leil et al., 2003; Yao et al., 2003).  
Furthermore, ERK2 but not ERK1 was necessary for H-Ras-induced epithelial-to-mesenchymal 
transformation in MCF-10A breast epithelial cells (Shin et al., 2010). RNAi silencing of either 
ERK1 or ERK2 impaired the growth of BRAF mutant melanoma cells (Qin et al., 2012). Together 
these observations suggest that ERK1 and ERK2 have distinct biological functions. Future studies 
will be needed to further characterize these distinct biological functions. 
Unlike the highly restricted substrates of the Raf and MEK isoforms, the ERK1 and ERK2 
(extracellular-signal regulated kinase) kinases are thought to share up to 200 substrates, in both 
nuclear and cytosolic compartments (Yoon and Seger, 2006).  Once activated ERK1 and ERK2 
can phosphorylate cytoplasmic substrates and additionally translocate into the nucleus and 
phosphorylate nuclear substrates.  
Multiple ERK substrates can contribute to the essential role of ERK in cancer growth. Key 
cytoplasmic substrates include the 90 kDa RSK (ribosomal S6 kinases) serine/threonine kinases 
(Romeo et al., 2012).  RSK proteins (RSK1-4) are regulators of diverse cellular processes, 
including cell proliferation, survival and motility. Other ERK substrates include the cytoplasmic 
MNK and nuclear MSK family kinases (Hauge and Frodin, 2006; Hou et al., 2012).  ERKs also 
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phosphorylate many nuclear transcription factors that include Ets family transcription factors (e.g., 
Elk-1), Fos and Myc.  ERK phosphorylation of Myc at S62 stabilizes Myc and prevents FBW7 E3 
ligase-mediated proteasomal degradation (Farrell and Sears, 2014).  
1.7 Raf-MEK-ERK target validation in Ras mutant cancers 
 
  The Raf-MEK-ERK signaling cascade has been rigorously validated as a necessary 
effector for Ras transformation (Cuadrado et al., 1993; Khosravi-Far et al., 1995; Khosravi-Far et 
al., 1996; White et al., 1995).  In early focus formation and clonogenic growth assays, several 
laboratories observed that dominant-negative mutants of Raf, MEK, or ERK effectively inhibited 
Ras-driven transformation (Cowley et al., 1994; Kolch et al., 1991; Schaap et al., 1993).  
Consistent with the importance of Raf-MEK-ERK signaling, it was also demonstrated that the Ras 
effector domain mutant T35G, which preferentially impairs Ras-Raf interaction relative to PI3K 
and RalGEF, inhibited H-Ras transforming capabilities in NIH 3T3 mouse fibroblasts (White et al., 
1995). Expression of activated Raf-1 could overcome growth inhibition associated with loss of 
Ras or expression of Ras dominant negative mutant S17N (Feig and Cooper, 1988). Finally, 
genetic loss of all three RAS isoforms causes growth cessation of mouse embryo fibroblasts and 
only activated Raf (and not PI3K and/or RalGEF) could rescue the growth defect of “Rasless” 
cells (Drosten et al., 2010). Activated MEK or ERK could also partially restore growth. Together 
these initial observations demonstrated that the Raf-MEK-ERK signal cascade was both 
downstream of Ras in mammalian cells and necessary for Ras transformation. 
Raf has been validated extensively in human cancer cell lines as a target for therapies 
(Hingorani et al., 2003a; Hoeflich et al., 2006; Karasarides et al., 2004; Sharma et al., 2005; 
Sumimoto et al., 2006).  This is a direct consequence of its mutational activation, as well as, 
mutual exclusivity from Ras mutations in cancers (Davies et al., 2002; Karasarides et al., 2004; 
Rajagopalan et al., 2002; Sieben et al., 2004; Singer et al., 2003).  The non-overlapping 
occurrence of Raf and Ras mutations in some cancer types (e.g., melanoma, colorectal cancer) 
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suggests that Raf is likely the most significant downstream effector in these Ras mutant cancers.  
This contrasts with activating mutations in PIK3CA (encodes p110α that can occur together with 
RAS mutations. Consistent with this observation, several studies have validated the role of Raf 
downstream of mutant Ras in colorectal, pancreatic and lung tumor cell lines (Campbell et al., 
2007; Li et al., 2013; Subramanian and Yamakawa, 2012).  Together these data suggest that 
therapies for Ras mutant cancer treatments should be, at least partially, focused on targeting the 
Raf-MEK-ERK signaling cascade.   
While RNAi use in cell culture is a strong tool for validating the importance of a cancer 
target, there are several caveats associated with genetic manipulation and its translation into 
actual cancer therapies.  First, in vivo RNAi targeting is still under investigation and far from use 
as an effective therapy.  As such, our most effective tools for cancer treatment are still targeted 
small molecule inhibitors.  Inhibitors, generally, block catalytic function or prevent protein-protein 
activation, however RNAi targets the entire protein for depletion, which is vastly distinct from 
catalytic or allosteric inhibition.  Though RNAi is far from ideal, it still remains a powerful tool for 
targeted drug discovery.    
Raf has also been sufficiently validated as an in vivo target for mutant Ras-driven cancer 
initiation and progression. The two-stage chemical carcinogenesis model, where a single 
treatment with the mutagen 7,12-dimethylbenz[a]anthracene (DMBA) is followed by repeated 
applications of a pro-inflammatory phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) 
causes Hras Q61L-induced squamous cell carcinomas has been widely used to assess the role 
of Ras effectors (e.g., Tiam1, RalGDS, PLCε, and p110α) in cancer formation (Bai et al., 2004; 
Gupta et al., 2007; Malliri et al., 2002; Slack-Davis et al., 2003).  Using this mouse model, 
Baccarini and colleagues showed that conditional loss of one Craf in the epidermal tissue reduced 
the number of tumors as well as tumor size, with complete inhibition of tumor formation upon loss 
of both c-Raf alleles (Ehrenreiter et al., 2009). Extending this to Kras-driven cancers, two separate 
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studies observed that Craf but not Braf deficiency impaired Kras G12D-induced lung tumor 
formation (Blasco et al., 2011; Karreth et al., 2011).  However, in contrast to these studies, Craf 
was found to be dispensable for Kras G12D-induced pancreatic cancer formation (Eser et al., 
2013). While a role for Braf was not addressed in this study, the finding by McMahon and 
colleagues that activated Braf V600E alone could phenocopy activated Kras G12D and induce 
pancreatic cancer formation suggests that different RAF isoforms may drive KRAS-driven cancer 
development in different tissues (Collisson et al., 2012).   
The studies above provide validation that Raf is necessary for tumor initiation and 
progression. However, whether Raf plays a role in mutant Ras tumor maintenance remains 
partially answered.  Counter and colleagues observed that ERK plays a role in tumor maintenance 
of Ras transformed cells, as an inducible dominant-negative MEK prevented continued tumor 
growth in a xenograft mouse model (Lim and Counter, 2005).  However, their key finding was that 
a membrane-targeted, activated, variant of p110α, not c-Raf, was sufficient to maintain 
tumorigenic growth of KRAS mutant human colon and pancreatic cancer cell lines when KRAS 
expression was ablated.  This result suggests that PI3K rather than Raf inhibition will be required 
to block the KRAS mutant tumor growth.  
Use of genetic knockout mouse models where effector function is ablated concurrently 
with RAS activation addresses the role of that effector in tumor initiation and progression but not 
maintenance.  Additionally, genetic ablation of an effector, resulting in loss of protein expression, 
is not an accurate modeling of the consequences of pharmacologic inhibition of the catalytic 
function of the effector.  With the development of potent and selective pharmacologic inhibitors of 
the Raf-MEK-ERK cascade, the limitations in these studies can be overcome. However, they still 
face the limitations of our current mouse models of cancer (Colvin and Scarlett, 2014). Orthotopic 
tumors induced by implantation of human tumor cells into immunocompromised mice provide 
another model. However, with the obvious importance of the immune system in host response to 
tumor growth, these studies cannot evaluate drug response in the context of an intact immune 
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response. Genetically engineered mouse models overcome these limitations. However, since 
tumor develop is initiated by one or two genetic alterations, they are genetically less complex than 
bona fide human cancers.  
1.8 Targeting RAS for cancer Treatment 
 
As indicated above, the current therapeutic options for PDAC are limited and ineffective. 
With the high frequency of KRAS mutations in this cancer and strong preclinical evidence that 
disruption of KRAS function will impair cancer growth, the development of effective anti-KRAS 
inhibitors has been actively pursued.  However, despite more than three decades of intensive 
effort by the pharmaceutical industry and academia, to date, no effective therapeutic strategies 
have reached the clinic (Bryant et al., 2014; Stephen et al., 2014).  In this section, we provide a 
summary of past and ongoing efforts to develop anti-Ras therapeutic strategies (Figure 1.9). 
As described above, the Ras C-terminal CAAX motif signals for posttranslational 
modifications that promote Ras membrane association.  That mutation of the cysteine residue to 
serine (SAAX) to prevent the addition of the farnesyl isoprenoid lipid or truncation of the AAX 
residues results in completely inactive Ras proteins supported the rationale to target 
farnesyltransferase as a therapeutic strategy (Berndt et al., 2011).  Numerous companies 
successfully developed potent and selective farnesyltransferase inhibitors (FTIs), with two 
(tipifarnib and lonafarnib) advancing to Phase III clinical evaluation (Basso et al., 2006).  Despite 
promising cell culture and mouse model observations with FTIs, FTIs failed to show any clinical 
benefit in pancreatic and colorectal cancer patients. Their failure was attributed to the earlier 
finding that the K-Ras and N-Ras proteins, when FTase activity is blocked, can then serve as a 
substrate for the related geranylgeranyltransferase-I enzyme  (GGTase-I), and be modified by the 
related geranylgeranylgeranyl isoprenoid lipid (Figure 1.3).  Since geranylgeranylgeranyl-
modified Ras retains the ability to be membrane-associated and transforming, this bypass 
mechanism prevented the effectiveness of FTIs for KRAS mutant cancers. 
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Currently, alternative strategies to disrupt Ras membrane association are being 
considered. These include targeting the other two CAAX motification enzymes, ICMT and Rce1 
(Figure 1.3). Another approach are farnesyl lipid mimics, salirasib, that act apparently by 
competing for Ras membrane association (Bustinza-Linares et al., 2010).  More recently, 
inhibitors of a chaperone protein, the prenyl-binding protein phosphodiesterase 6 delta that 
modulates Ras trafficking to the plasma membrane have been described (Chandra et al., 2012; 
Zimmermann et al., 2013). 
The most aggressively pursued anti-Ras strategy involves inhibition of Ras downstream 
effector signaling.  However, these efforts are complicated by the fact that Ras uses multiple 
effectors to promote cancer growth (Mitin et al., 2005).  Of these effector pathways, the Raf (A-
Raf, B-Raf and C-Raf) and class I phosphatidylinositol-3 kinases (PI3K; p110α, γ and δ) effector 
pathways have attracted the greatest interest (Fritsch et al., 2013; Nissan et al., 2013), with 
multiple inhibitors of components of each pathway currently under clinical evaluation. That these 
effector pathways have driver functions in KRAS-dependent cancer growth is supported by their 
frequent mutational activation in cancer: BRAF (20%) and PIK3CA (encodes p110α; 12%) 
(COSMIC). However, when applied as monotherapies, these inhibitors have shown limited to no 
clinical activity in RAS mutant cancers.  There are numerous ongoing clinical trials evaluating 
whether concurrent inhibition of Raf and PI3K effector signaling will be more effective 
(http://clinicaltrials.gov/).  
An approach once thought impossible involves direct inhibition of mutant Ras.  Initial 
efforts to disrupt GTP binding were not successful, due to the picomolar affinity of GTP binding to 
Ras. This contrasts with the low micromolar binding affinity of ATP to protein kinases, where 
effective ATP-competitive protein kinase inhibitors have been developed successfully.  Similarly, 
efforts to identify small molecules that can act as a GAP for mutant Ras proteins did not succeed.  
Recently, small molecules that directly bind Ras and perturb either RasGEF activation or ef
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binding have been described (Maurer et al., 2012; Ostrem et al., 2013; Sun et al., 2012). Whether 
these early stage Ras binders can be advanced to more potent and selective Ras binding 
molecules and whether they can effectively block the critical functions of Ras to have a clinical 
consequence remains to be determined. 
Other directions considered for anti-Ras drug discovery include targeting the metabolic 
changes in glucose and glutamine metabolism found in RAS mutant cancers (Ahearn et al., 2012; 
Sun et al., 2012).  RNAi targeting of RAS gene expression is also being pursued.  Here, whether 
these can be effectively delivered to the cancer, and whether sufficient suppression of RAS gene 
expression can be achieved, are the current uncertainties in these directions. Finally, unbiased 
RNA interference screening has been applied to search for synthetic lethal interactors of mutant 
RAS. However, these studies have been hampered by the lack of reproducibility in the findings 
(Luo et al., 2012; Weiwer et al., 2012). 
1.8.1 Pharmacologic Inhibition of Raf-MEK-ERK signaling in mutant RAS cancers 
Pharmacologic inhibitors of Raf have not been effective against RAS mutant cancers. 
Their ineffectiveness is due to the paradoxical activation rather than inactivation of ERK signaling 
(Figure 1.10A).  Studies in cell culture and mouse models determined that Raf inhibitor treatment 
caused the formation of B-Raf/C-Raf heterodimers that are dependent on activated Ras (Heidorn 
et al., 2010). Ras activation promotes Raf dimerization, primarily B-Raf/C-Raf heterodimers. In 
the Raf dimmer, B-Raf is inhibited, but it then causes activation of the non-inhibited C-Raf 
molecule.  Only at high inhibitor concentrations that cannot be achieved in the patient are both 
Raf molecules inhibited and ERK signaling is blocked.  To date, the most successful Raf inhibitor 
is vemurafenib (Zelboraf), which targets mutant B-Raf V600E in melanoma (Flaherty et al., 2010).  
A second Raf inhibitor, dabrafenib (Tafinlar), was later approved for the same patient population. 
However, its success has been complicated by the re-occurrence of tumors harboring Ras 
mutations (Nazarian et al., 2010). In one study, vemurafenib inhibition caused accelerated ERK 
signaling resulting in aberrant growth and tumor formation in tissues, which harbored mutant RAS. 
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Although developed originally as a C-Raf inhibitor, sorafenib is a multi-kinase inhibitor that also 
inhibitors RTKs involved in tumor angiogenesis.  Therefore, its clinical activity is not attributed to 
its Raf inhibitory activity.  A number of additional Raf inhibitors are currently under clinical 
evaluation (Figure 1.11). Currently, efforts to develop Raf inhibitors that do not promote Raf 
dimerization or have more pan-Raf inhibitory activities, or inhibitors of Raf dimerization, are being 
pursued to overcome the limitation of first generation Raf inhibitors.  
MEK inhibitors have also shown limited to no anti-tumor efficacy in RAS mutant cancers. 
For example, Rosen and colleagues found that MEK inhibitor treatment was effective against 
BRAF but not RAS mutant human cancer cell lines (Daouti et al., 2010; Solit et al., 2006).  MEK 
inhibition alone was not effective in a mouse model of Kras-driven lung cancer formation 
(Engelman et al., 2008).  The ineffectiveness of MEK inhibition is attributed to the loss of ERK 
activation induced feedback inhibitory mechanisms (Figure 1.10B).  Flux through the Raf-MEK-
ERK cascade requires critical regulation, with high levels of activated ERK causing growth 
suppression; ERK activation induces feedback inhibition mechanisms that dampen upstream 
activators of the pathway (Figure 6).  These mechanisms include ERK phosphorylation of Raf to 
dampen Ras activation of Raf (Dougherty et al., 2005).  Other feedback mechanisms include ERK 
phosphorylation of Sos1 or the EGFR, or transcription factor-mediated induction of gene 
expression of negative regulators such as DUSP protein phosphatases (Little et al., 2011; Pratilas 
et al., 2009; Wagle et al., 2014) or Sprouty (Roskoski, 2010). In a recent unbiased approach to 
define mechanisms that drive resistance to MEK inhibition, Johnson and colleagues showed that 
MEK inhibition of KRAS mutant breast cancer cell lines resulted in the activation of multiple RTKs 
(Duncan et al., 2012).  They further showed that concurrent inhibition of RTK activation then 
enhanced the anti-tumor activity of MEK inhibition in vitro and in vivo.  One MEK1/2 inhibitor 
(trametinib/Mekinist) has been approved for use alone, or together with the Raf inhibitor 
dabrafenib, for BRAF mutant melanoma (Figure 1.11). Trametinib is an allosteric, non-ATP 
competitive inhibitor that prevents activated MEK1/2 phosphorylation of its substrates. There are 
	 18	
at least 16 additional MEK1/2 inhibitors under clinical evaluation (Figure 8), many also allosteric 
non-ATP competitive inhibitors. One unique inhibitor, RO5126766, inhibits MEK and additionally 
Raf, making it less susceptible to the feedback activation of Raf caused by ERK inhibition. 
With the ineffectiveness of anti-Raf and –MEK therapies in RAS mutant cancers due 
largely to kinome reprogramming mechanisms that caused reactivation of ERK, it prompted 
studies to address whether inhibition of ERK directly may overcome these limitations.  Recently, 
it was shown that an ERK1/2-selective inhibitor, SCH772984, was active in Raf- and MEK-
resistant BRAF mutant melanoma in preclinical models (Morris et al., 2013).  SCH772984 binds 
ERK, preventing MEK phosphorylation and activation of ERK and additionally preventing ATP 
binding and ERK phosphorylation of its substrates. Additionally, another group described another 
ERK inhibitor capable of overcoming resistance to MEK inhibitors (Hatzivassiliou et al., 2012).  
Furthermore, Genetech also produced an ERK inhibitor that is currently being evaluated in pre-
clinical models.   
ERK inhibition represents a new approach to blocking an old pathway; however, the 
question remains whether ERK inhibition as a therapy will be successful in combating RAS mutant 
cancers, or succumb to some of the limitations associated with Raf and MEK inhibition. Currently, 
three ERK inhibitors are under clinical evaluation (MK-8353/SCH 900353 is an orally available 
analog of SCH772984) (Figure 1.11).  
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Figure 1.1 
 
Figure 1.1 Human Ras proteins.  The three RAS genes encode four highly related 188/189 
amino acid Ras proteins.  The two highly related K-Ras 4A and 4B isoforms (90% identical) arise 
from alternative gene splicing and utilization of alternative fourth exons 4A and 4B.  The numbers 
indicate percent sequence identity with H-Ras (83-85%). Residues 1-164 comprise the G domain 
that binds and hydrolyses GTP and includes the switch I (SI; aa 30-38) and II (SII; aa 60-76) 
sequences that change in conformation during GDP-GTP cycling. The core effector domain (E; 
residues 32-40) is essential for Ras-GTP binding to downstream effectors. The predominant 
missense mutations (~99%) found in cancer result in single amino acid substitutions at residues 
12, 13 or 61. Ras proteins diverge in their C-terminal sequences comprised of the hypervariable 
domain (HVD). 
 
 
 
 
 
 
 
 
 
 
	 20	
Figure 1.2. 
 
 
 
Figure 1.2. Regulation of the Ras GDP-GTP cycle. Ras proteins act as molecular switches 
alternating between GTP- (active state) and GDP- (inactive state) bound states, where Ras-GTP 
binds preferentially to downstream effectors (E).  There are two classes of regulatory proteins that 
regulate this cycling process: RasGEFs (guanine exchange factors) and RasGAPs (GTPase 
activating proteins).  In resting cells, normal Ras is predominantly GDP-bound (~95%).  Upon 
growth factor stimulation and activation of RasGEF, rapid and transient GDP-GTP exchange is 
stimulated. RasGAP stimulation of the intrinsic GTPase activity and GTP hydrolysis restores the 
inactive Ras-GDP state. Mutant Ras proteins are impaired in their intrinsic and GAP-stimulated 
GTP hydrolysis activities, resulting in stimulus-independent, persistent Ras-GTP formation 
(~80%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
JKL JML
L7
#$%JGN
#$%J,L
GOO15<>9%
#$% #$%
JKLJML
P74$5<781Q P$5<781Q
	 21	
Figure 1.3. 
 
 
 
Figure 1.3. Ras proteins and membrane association. Ras proteins are synthesized initially as 
cytosolic and inactive proteins.  Within minutes, they undergo a series of posttranslational 
modifications signaled by the C-terminal CAAX motif. First, cytosolic farnesyltransferase (FTase) 
catalyzes covalent, irreversible addition of a C15 isoprenoid lipid to the cysteine residue of the C-
terminal CAAX motif.  This then allows Rce1-catalyzed proteolytic removal of the AAX residues 
and Icmt-catalyzed, reversible carboxylmethylation (-OMe) of the now terminal farnesylated 
cysteine.  H-Ras is the only Ras isoform that is solely modified by FTase.  Although normally also 
FTase substrates, when FTase activity is blocked by FTase inhibitor (FTI) treatment, K-Ras and 
N-Ras, can now be modified by geranylgeranyltransferase-I (GGTase-I)-catalyzed addition of a 
related C20 geranylgeranyl isoprenoid, resulting in membrane association. 
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Figure 1.4. 
 
 
Figure 1.4.  PDAC genetic progression model. KRAS mutations occur early in cancer 
progression followed by loss of important tumor suppressors. KRAS mutation is the initiating step 
in PDAC development, followed by mutational loss of the CDKN2A, TP53 and SMAD4 tumor 
suppressors.  KRAS is the RAS isoform predominantly mutated in PDAC (98% of all RAS 
mutations). 
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Table 1.1. 
 
Table 1.1. Frequency of RAS mutations in human cancers 
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Figure 1.5. 
 
 
Figure 1.5. Ras effector signaling. Ras-GTP binds preferentially to 11 catalytically-distinct 
classes of effectors.  Cell culture and/or mouse model studies have been implicated six classes 
in Ras-mediated tumor initiation, progression and/or maintenance.  This includes the Raf, p110 
catalytic subunits of class I PI3Ks, GEFs for the Ral small GTPases (RalGEFs; RalGDS, Rgl, 
Rgl2 and Rgl3) and Rac small GTPase (Tiam1) and PLCe whose functions are necessary for 
tumor growth. In contrast, RASSF1A family members are negative regulators and their expression 
is lost in cancer.  
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Figure 1.6.
 
 
Figure 1.6. Components of the Raf-MEK-ERK protein kinase cascade. Shown are the human 
proteins, with domain structure determined in SMART.  The percentages of overall protein and 
kinase domain amino acid identities are indicated (%) and were determined by ClustalW multiple 
sequence alignment analyses. The phosphorylation sites that regulate Raf kinase activity are 
complex and include both positive (green) and negative (red) phosphorylation events.  We have 
not included all known phosphorylation sites and have included only select key phosphorylation 
sites. The negative regulatory sites are conserved in all Raf isoforms and serve as recognition 
sites for 14-3-3 dimer binding and inhibition of Raf. Phosphorylation of S432(A-Raf)/S579(B-
Raf)/S471(C-Raf) is important for Raf interaction with MEK. Raf phosphorylation sites in MEK1/2 
and MEK1/2 phosphorylation sites in ERK1/2 are indicated. The V600E amino acid substitution 
comprises ~80% of cancer-associated activating mutations in B-Raf. Abbreviations are: RBD, 
Ras-binding domain, CRD, cysteine-rich domain; S/T, serine/threonine; S/T/Y, 
serine/threonine/tyrosine.   
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Figure 1.7. Regulation of Raf dimerization and activation. Ras-GTP recruits Raf to the plasma 
membrane. Here PP1 or PP2A dephosphorylate Raf in its inhibitory domain.  This event primes 
Raf interaction with Ras-GTP and promotes several important phosphorylation events. Once 
phosphorylated Raf proteins dimerization and are considered active. PP5 and PP2A 
dephosphorylate each Raf monomer leading to dissociation from the plasma membrane and 
monomerization.  Finally, PKA phosphorylates Raf leading it to adopt a closed, “inactive,” 
confirmation.  
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Figure 1.8. 
 
 
Figure 1.8. Receptor tyrosine kinase-mediated activation of wild type Ras. Wild-type Ras 
activation occurs when ligands (e.g., epidermal growth factor; EGF) stimulate activation of 
receptor tyrosine kinases (RTK; e.g., EGF receptor).  Once stimulated, RTKs autophosphorylate 
tyrosine residues in the cytoplasmic domain, creating docking sites for Src homology 2 (SH2) 
domain-containing proteins (e.g., Grb2).  The tandem SH2 domains of Grb2 interact with proline-
rich sequences in the Sos1 RasGEF, promoting Sos1 translocation to the plasma membrane, 
leading to activation of membrane-associated Ras.  Sos1-mediated formation of Ras-GTP then 
promotes Ras association with Raf, leading to activation of the ERK MAPK cascade.  Shown here 
is KSR association with Raf, MEK and ERK.  KSR is but one of a number of scaffolding proteins 
that associate with one or more components of the three-tiered protein kinase cascade.  Scaffolds 
modulate the composition of the pathway and additional influence temporal and spatial activity of 
ERK signaling.  Other ERK scaffolds include IQGAP1, MP1, Sef and b-arrestin. 
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Figure 1.9. 
 
Figure 1.9. Approaches for the development of anti-Ras drugs.  Once considered impossible, 
recent studies have identified direct Ras binding small molecules that alter Ras function. 
Approaches to inhibit Ras membrane association include the development of farnesyltransferase 
inhibitors. Inhibitors of Ras effector signaling, in particular the Raf-MEK-ERK protein kinase 
cascade comprise the most active direction of anti-Ras drug discovery.  Unbiased functional 
siRNA/shRNA library screens have identified genes that when suppressed, cause growth 
suppression of RAS mutant but not RAS wild type tumor cells.  The identified synthetic lethal 
interactors (X) typically involve components that have no direct association with Ras signaling.  
Recently, with evidence that mutant RAS causes altered glucose and glutamine metabolism, 
approaches to target metabolism have also been considered. 
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Figure 1.10. 
 
Figure 1.10. Mechanisms of RAS mutant cancer cell resistance to Raf or MEK inhibitors.  
(A). RAS mutant cancer cells exhibit paradoxical activation rather than inactivation of ERK 
signaling. (B) RAS mutant cancer cells exhibit multiple mechanisms of resistance to MEK 
inhibition.  The mechanisms that relate to RTK and Sos activation of Ras are not expected to be 
relevant for mutant (*) Ras activity, since it is already persistently GTP-bound due to GAP 
insensitivity.  However, since there is evidence that wild type (WT) Ras proteins support mutant 
Ras in cancer growth, these feedback mechanisms are then still important even in RAS mutant 
cancer cells. 
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Figure 1.11. 
 
 
Figure 1.11. Pharmacologic inhibitors of Raf-MEK-ERK under clinical evaluation. Compiled 
from ClinicalTrials.gov.  Past and/or ongoing approaches for targeting Ras include direct Ras 
binders and inhibitors of Ras function and inhibition of Ras membrane association.  Functional 
si/shRNA library screens have been applied to identify genes (x), that when silenced, impair the 
growth of RAS mutant but not wild type tumor cell lines (aka synthetic lethal interactors of mutant 
Ras). *FDA-approved for the treatment of renal cell, hepatocellular and thyroid carcinoma; +FDA-
approved for the treatment of BRAF-mutant melanoma. 
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CHAPTER 2: PROLONGED ERK INHIBITION IN KRAS-MUTANT PANCREATIC CANCER IS 
ASSOCIATED WITH MYC DEGRADATION AND SENESCENCE-LIKE GROWTH 
SUSPRESSON1 
 
INTRODUCTION 
Mutational activation of KRAS is found in >95% of pancreatic ductal adenocarcinomas 
(PDAC) (Bryant et al., 2014).  With strong and compelling evidence that the continued function of 
mutant KRAS is essential for PDAC maintenance, there has been intense effort in developing 
pharmacologic approaches to block mutationally activated KRAS for cancer treatment (Cox et al., 
2014; Stephen et al., 2014). Currently the most promising strategy involves inhibitors of RAS 
effector signaling, in particular the RAF serine/threonine kinases (Cox et al., 2014; Stephen et al., 
2014). Activated RAS binds to RAF and promotes its activation. RAF then phosphorylates and 
activates the MEK1 and MEK2 dual specificity protein kinases, which in turn phosphorylate the 
related ERK1 and ERK2 MAPKs. Activated ERK1/2 then phosphorylate more than 200 substrates 
(Yoon and Seger, 2006).   
The limited substrates of RAF and MEK prompted earlier assumptions that pharmacologic 
inhibitors of either kinase would be equivalent and equally effective in blocking ERK activation. 
This led to the development and evaluation of small molecule inhibitors of RAF or MEK, with at 
least 27 under clinical evaluation (ClinicalTrials.gov). However, RAF kinase inhibitors have been 
ineffective in RAS-mutant cancers as a consequence of paradoxical induction of Ras-dependent 
RAF dimerization and activation, with subsequent enhanced ERK activation (Lito et al., 2013). 
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MEK inhibitors have shown limited to no activity in RAS-mutant cancers, most commonly 
attributed to loss of ERK feedback inhibition and compensatory mechanisms that cause 
reactivation of ERK (Samatar and Poulikakos, 2014).  1 
Since reactivation of ERK is a major mechanism overcoming RAF or MEK inhibitor 
efficacy, we hypothesized that direct inhibition of ERK may overcome these limitations. In support 
of this, we recently described the development of a ERK1/2-selective pharmacologic inhibitor  
(SCH772984) and showed that BRAF-mutant melanomas with acquired resistance to RAF and/or 
to MEK inhibitors were still sensitive to ERK1/2-selective pharmacologic inhibitors (Hatzivassiliou 
et al., 2012; Morris et al., 2013). ERK inhibition suppressed the growth of ~50% of RAS-mutant 
human tumor cell lines in vitro. However, the mechanisms behind ERK inhibitor susceptibility 
versus resistance of subsets of RAS-mutant cancers remain unresolved (Hatzivassiliou et al., 
2012). In the present study we assessed the mechanistic basis of ERK inhibitor sensitivity in 
KRAS-mutant PDAC, and applied unbiased chemical and genetic library screens to identify 
combination approaches to enhance anti-ERK therapies.   
RESULTS 
MEK Inhibitor-Resistant PDAC Cell Lines Are Sensitive to ERK Inhibitor 
Our recent analyses showed that the ERK1/2-selective inhibitor SCH772984 potently 
suppressed the growth of ~50% of RAS-mutant human tumor cell lines in vitro (Morris et al., 
2013). However, the mechanistic bases for ERK inhibitor sensitivity and de novo resistance were 
not addressed. Since PDAC is the most KRAS-addicted cancer, we first focused on evaluating 
SCH772984 in a panel of 11 KRAS-mutant PDAC cell lines (Table 2.1).  Anchorage-dependent 
proliferation was monitored for 72 hr (Figure 2.1A). We found that five cell lines were sensitive to 
SCH772984 (GI50 <4 µM), whereas six exhibited de novo resistance (GI50 >4 µM). Surprisingly, 
three out of four SCH772984-sensitive cell lines were resistant to the MEK inhibitor selumetinib 
                                            
1 Hayes et al. Cancer Cell, in press 
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(Figure 2.1B), independent of the degree of suppression of ERK phosphorylation (Figure 2.2C).  
Thus, inhibition of the pathway at the level of ERK has distinct consequences from inhibition at 
the level of MEK.   
We next expanded our panel of KRAS-mutant pancreatic cancer cell lines to include those 
derived from PDAC patient-derived xenografts (Table 2.2).  Interestingly, we found a similar 
pattern of sensitivity to SCH772984, where some cell lines were sensitive and others were 
resistant (Figure 2.2A).  We observed that treatment with a chemically and mechanistically distinct 
ERK inhibitor, BVD-523 (ulixertinib), a current clinical candidate (NCT01781429) (Germann, 
2015), resulted in a similar pattern of sensitivity in both established and PDX cell lines (Figure 
2.2A and 2.2B).    
ERK Inhibitor Sensitivity Is Not Associated with KRAS Dependency or with K-Ras-dependent 
Effector Signaling 
Previous studies showed that only a subset of KRAS-mutant PDAC cell lines exhibited 
KRAS dependency (Singh et al., 2009). To determine if KRAS dependency correlates with 
sensitivity to SCH772984, we evaluated the consequence of transient siRNA-mediated 
suppression of KRAS expression in our cell lines (Figure 2.1C). KRAS knockdown resulted in 
~50% reduction in anchorage-dependent viability (Figures 2.1D and 2.2D) and 50% or greater 
reduction in clonogenic growth (Figures 2.1E and 2.2E). Using the same shRNA KRAS vectors 
used in the previous study (Singh et al., 2009), we established mass populations of stably infected 
cells displaying >80% reduction in K-Ras4B protein (Figure 2.2F). We found >50% reduction in 
both anchorage-dependent and anchorage-independent growth in all cell lines (Figures 2.2G and 
2.2H). We conclude that KRAS-dependent growth is not a predictor of ERK inhibitor sensitivity. 
 We next determined whether ERK inhibitor sensitivity correlates with K-Ras-dependent 
ERK activation. Neither transient nor sustained KRAS suppression reproducibly suppressed 
pERK in any cell line (Figures 2.1C and 2.2F). Transient KRAS suppression significantly reduced 
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pAKT in 3 of 9 cell lines, whereas stable suppression did not. Thus, SCH772984 sensitivity was 
not associated with K-Ras-dependent ERK or AKT activation. 
Short-term Treatment with SCH772984 Enhances Apoptosis and Alters Cell Cycle Regulation 
Next, we investigated the mechanism of SCH772984-induced growth suppression. After 
72 hr treatment, we observed a significant fraction of non-adherent cells in the sensitive cell lines.  
Enhanced caspase-3 cleavage was detected in both non-adherent (Figure 2.3A) and adherent 
(Figure 2.4A) cell populations.   
We then determined if ERK inhibition perturbed cell cycle progression. Using flow 
cytometry, we observed that three of four sensitive cell lines showed a significant treatment-
induced increase in cells in G0/G1 and a concomitant decrease in cells in S and G2/M (Figure 
2.3B). Treated cell lines also exhibited reduced levels of cyclin D1 and B1, regulators of 
progression through G1 and M, respectively, as well as hypophosphorylation and activation of RB, 
and reduced p21 protein levels (Figure 2.3C).  Additionally, we found that sensitive cell lines 
exhibited increased sensitivity to SCH772984 over time as measured by changes in GI50 values 
(Figure 2.4B).  We conclude that short-term treatment with SCH772984 suppresses PDAC tumor 
cell growth by enhancing apoptosis and/or by impairing progression through G1 and mitosis. 
ERK Inhibitor Induction of AKT Activation Is a Marker of Sensitivity 
Rapid ERK inhibitor-induced kinome reprogramming may cause dynamic changes in the 
activities of signaling components that distinguish sensitive from resistant cell lines (Duncan et 
al., 2012). Therefore, we evaluated signaling changes caused by SCH772984 treatment at 4, 24 
and 72 hr.  We monitored the consequences of both mechanisms of SCH772984 inhibition of 
ERK (Morris et al., 2013): inhibition of MEK1/2 binding and phosphorylation of ERK1/2, and 
inhibition of ATP binding and ERK1/2 phosphorylation of their cytoplasmic substrate, p90 RSK. 
After 4 hr, pERK and pRSK levels were reduced in both sensitive and resistant cell lines (Figure 
2.5A). After 24 hr, pERK but not pRSK levels rebounded over vehicle control levels in both 
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sensitive and resistant cell lines. However, by 72 hr, pERK increased further in a dose-dependent 
manner, whereas pRSK levels remained reduced even at 72 hr (Figures 2.6A and 2.6C).  Thus, 
kinome reprogramming overcomes SCH772984 inhibition of ERK phosphorylation by MEK, but 
not ERK signaling, in both sensitive and resistant cell lines. 
We next determined a basis for the transient and reversible suppression of ERK1/2 
phosphorylation by SCH772984. Treatment with SCH772984 for 72 hr caused suppression of the 
ERK phosphatase DUSP4 in 5 of 6 cell lines, which could contribute to pERK restoration (Figures 
2.5B and 2.6E). However, an alternative mechanism was suggested by the increased levels of 
pMEK1/2 observed at 4 and 24 hr (Figure 2.5A and 2.6B), indicating potential loss of ERK-
mediated negative feedback inhibition of KRAS-RAF-MEK signaling (Dougherty et al., 2005). 
Consistent with this possibility, concurrent treatment with the MEK inhibitor selumetinib prevented 
the increase in pERK1/2 (Figure 2.5C).  Furthermore, SCH772984 both reduced ERK-mediated 
phosphorylation of CRAF at S289/296/301 and increased phosphorylation at S338, a marker of 
CRAF activation (Figures 2.5D and 2.6D).  Thus, SCH772984-initiated loss of ERK-dependent 
negative feedback leads to increased CRAF and MEK activation in both sensitive and resistant 
cell lines without inducing the restoration of active ERK signaling as measured by pRSK. 
MEK inhibitor treatment has been linked to activation of phosphatidylinositol-3 kinase 
(PI3K)-AKT serine/threonine kinase signaling to re-sensitize BRAF inhibitor-resistant melanoma 
cell lines (Villanueva et al., 2010). Therefore, we determined whether phosphorylation of the PI3K 
substrate AKT was also elevated as a consequence of SCH772984 treatment in our sensitive cell 
lines. Consistent with that previous study (Villanueva et al., 2010), we observed a dose-dependent 
increase in pAKT at 72 hr in all sensitive but not resistant cell lines (Figure 2.6B and 2.6D).  Next, 
we expanded our analysis to the PDX cell lines.  We found that 66% of sensitive cell lines 
exhibited increased levels of pAKT (Figure 2.6G). Thus, treatment-induced pAKT elevation 
provided a biomarker for ERK inhibitor sensitivity.   
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To assess whether increased AKT activation is a compensatory protective response to 
overcome ERK inhibition-induced growth suppression, we co-treated cells with both SCH772984 
and the PI3K inhibitor AZD8186 (Hancox et al., 2015) to block the ERK inhibitor-associated 
increases in pAKT (Figures 2.5F and 2.6F).  Concurrent PI3K inhibition increased growth 
inhibition in sensitive cell lines, associated with caspase-3 cleavage, but surprisingly not in 
resistant cell lines (Figure 2.5E).  SCH772984-sensitive PDX cell lines also exhibited synergy 
when exposed to the combination of SCH772984 and AZD8186 (Figure 2.6H).  Similarly, in 
sensitive cell lines we also observed synergy with BVD-523 in combination with PI3K inhibition 
(Figure 2.6I-J).  Together, our data suggest ERK and PI3K inhibitors as a potential clinically 
relevant combination therapy in KRAS-mutant PDAC.     
Mechanistically Diverse Inhibitor Combinations Synergistically Enhance the Growth Inhibitory 
Activity of ERK Inhibitor versus MEK Inhibitor  
Since we determined that concurrent inhibition of PI3K synergistically enhanced ERK 
inhibitor-induced anti-proliferative activity, we next performed an unbiased chemical library screen 
to identify additional combinations for SCH772984-based therapy.  We applied a chemical library, 
comprised of 304 approved cytotoxic chemotherapeutic drugs and clinically available molecularly 
targeted drugs (Pemovska et al., 2013), to two SCH772984-sensitive cell lines, and we 
additionally screened for combinations with selumetinib. Synergistic and antagonistic interactions 
were assessed by comparing the response to each drug in the drug collection in the presence or 
absence of SCH772984 or selumetinib (deltaDSS score).  DeltaDSS scores greater than 5 or less 
than -5 were cutoffs for likely synergistic or antagonistic interactions, respectively.  
Complementing our findings with the PI3K inhibitor AZD8186, additional inhibitors of PI3K 
signaling (mTOR, AKT and S6 kinase inhibitors) also enhanced SCH772984 activity in both cell 
lines (Figure 2.7). Interestingly, the drug interactions of SCH772984 and selumetinib were 
strikingly different.  For example, in HPAC cells, SCH772984, but not selumetinib, was synergistic 
with mTOR and AKT inhibitors, as well as with a bromodomain inhibitor (Figure 4, upper right 
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panels).  The latter results indicate distinct mechanisms of resistance to inhibitors of these two 
nodes of the ERK-MAPK cascade. 
Long-term ERK Inhibition Causes a Senescence-like Phenotype 
Since acquired resistance is a limitation of essentially all protein kinase inhibitor-based 
therapies, we expect that ERK inhibitor treatment will be similarly limited.  To investigate likely 
mechanisms of acquired resistance, we first attempted to select resistant subpopulations by long-
term high-dose inhibitor treatment of sensitive cells, an approach used widely with inhibitors of 
RAF and MEK (Samatar and Poulikakos, 2014). However, even after 2-3 months of SCH772984 
treatment, we did not observe outgrowth of ERK inhibitor-resistant cells.  Instead, treated cells 
remained quiescent and displayed a flattened cellular morphology characteristic of senescent 
cells (Campisi, 2013) (Figure 2.8A). To investigate whether they were indeed senescent, we 
determined if the treated cells exhibited elevated β-galactosidase activity, the only reliable marker 
of oncogene-induced senescence in pancreatic cancer (Caldwell et al., 2012). We found that 
treatment of sensitive cell lines with SCH772984 at 1x or 2x GI50 induced increased β-
galactosidase activity in ~60% of cells after 7 to 14 days (Figures 2.8A, 2.8B and 2.9E) or even 
72 hr (e.g., HPAF-II cells, Figure 2.9A and 2.9B). 
Mutant RAS-induced senescence can be prevented through loss of one of two tumor 
suppressor pathways: p53 and its target p21, or p16-mediated dephosphorylation and activation 
of RB (Campisi, 2013). We found that the p53-p21 pathway was not induced in either sensitive or 
resistant cell lines after 7 or 14 days of continuous exposure to SCH772984 (Figure 2.9C, 2.9F, 
2.9H, and 2.9K). However, sensitive cell lines displayed both induction of p16 and loss of 
phospho-RB (Figures 2.8C, 2.9C, and 2.9G).  Furthermore, we observed onset of senescence in 
the SCH772984-sensitive PDX cell lines (Figure 2.9M and 2.9N).  Thus, consistent with previous 
studies where loss of p16 was required to prevent KRAS-induced senescence in pancreatic 
cancer (Bardeesy et al., 2006; Eser et al., 2013), we suggest that restoration of p16 function upon 
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ERK inhibitor treatment in turn unmasked KRAS-induced senescence activity in sensitive PDAC 
cell lines.  
Senescence is conventionally an irreversible process. We found that removal of 
SCH772984 for as long as 14 days reversed neither the sustained β-galactosidase activity nor 
the reduced cell growth induced by 28 days of treatment (Figure 2.9O-R).  Additionally, p16 
protein expression remained high whereas Myc and pRB protein expression remained low after 
SCH772984 removal (Figure 2.9S and 2.9T). Thus, ERK inhibition induced an irreversible 
senescence-like phenotype. 
ERK inhibition-induced Degradation of MYC Is Necessary and Sufficient for Induction of 
Senescence 
Next, we determined the signaling mechanism whereby ERK inhibition induced this 
phenotype. Recently, one study showed that Ras activation-induced senescence was 
characterized by both high ERK activity and increased degradation of selected proteins 
(Deschenes-Simard et al., 2013). In contrast, we found that long-term ERK inhibitor treatment (7 
or 14 days) increased widespread protein ubiquitination in sensitive cell lines (Figures 2.8D, 2.8E, 
2.9D, 2.9I, 2.9J, and 2.9L). Thus, ERK inhibition may cause the degradation and loss of one or 
more specific ERK substrate(s) to induce senescence-like growth suppression.   
We next determined if long-term SCH772984 treatment caused loss of specific ERK 
substrates or gene targets with known roles in senescence. The MYC transcription factor is an 
ERK substrate, and loss of MYC induced tumor cell senescence by an RB- or p16-dependent 
mechanism (Ohtani et al., 2001; Wu et al., 2007). Altered expression of ERK-regulated ETS family 
transcription factors (Ets-1 and Ets-2) stimulated CDKN2A (encoding p16) gene expression in 
senescent fibroblasts (Ohtani et al., 2001; Wu et al., 2007). In BRAF-mutant melanoma, ERK 
stimulated AURKB gene transcription, and suppression of AURKB expression induced 
senescence (Bonet et al., 2012). We therefore determined if long-term treatment with SCH772984 
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altered the levels of ETS1, ETS2, MYC or Aurora B proteins. We found that 7-day treatment 
resulted in decreased their levels in sensitive cell lines (Figure 2.10A). 
Next, we investigated the mechanisms whereby SCH772984 modulates Aurora B, MYC, 
ETS1, and ETS2 protein levels. First, RT-PCR analyses revealed no reduction in mRNA levels of 
any of the four proteins after 7 days of treatment, suggesting posttranscriptional mechanisms 
(Figure 2.11A). ERK phosphorylation of MYC is known to prevent its degradation (Farrell and 
Sears, 2014), implying that ERK inhibition would enhance its degradation. Consistent with this 
possibility, the proteasome inhibitor MG132 restored the protein levels of ETS1, ETS2, and MYC 
in SCH772984-treated cells (Figures 2.10B, 2.10C and 2.11B).  
   MYC protein stability can be controlled in a multi-step process by RAS effector signaling 
(Farrell and Sears, 2014). ERK phosphorylation of MYC at residue S62 facilitates its subsequent 
phosphorylation at T58 by GSK3β, leading to proteasomal degradation. We found that 
SCH772984 induced loss of the majority of MYC protein.  Consistent with the current model, each 
sensitive cell line displayed hypophosphorylation at T58 in the remaining MYC protein (Figures 
2.10D, 2.10E and 2.11E). Furthermore, MYC ubiquitination was increased in sensitive cells after 
SCH772984 treatment (Figures 2.10F, 2.11C and 2.11D). Interestingly, the remaining low level 
of MYC was hyperphosphorylated at S62 in HPAF-II cells, suggesting ERK-independent 
phosphorylation at S62 in these cells. 
We then determined whether loss of MYC is a driver of the SCH772984-induced 
senescence-like phenotype, using a well-characterized MYC variant in which the T58 
phosphorylation site is substituted with an alanine residue (T58A) to prevent degradation by the 
proteasome (Yeh et al., 2004).  We found that Panc10.05 and HPAC cells ectopically expressing 
MYC T58A partially retained MYC expression upon SCH772984 treatment (Figure 2.10G), and 
that induction of β-galactosidase activity was significantly inhibited (Figure 2.10H and 2.10I). 
Conversely, depletion of MYC with siRNA in both sensitive and resistant cell lines was associated 
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with increased β-galactosidase activity (Figure 2.11F-I).  Thus, loss of MYC is necessary and 
sufficient to cause senescence-associated increased β-galactosidase activity. 
Since we noted that MYC T58A protein stability unexpectedly decreased upon ERK 
inhibition, we assessed the requirements for phosphorylation at S62 and T58 to modulate 
SCH772984-mediated loss of MYC protein.  Our analyses indicated that the regulation of MYC 
protein stability by ERK signaling is more complex than currently understood and must involve 
additional phosphorylation events and sites (Figure 2.11J-W). 
SCH772984 Treatment Reduces Tumor Xenograft Growth and MYC Protein Levels in vivo 
We next determined if loss of MYC also correlated with sensitivity to SCH772984 in vivo. We first 
determined the ability of SCH772984 to inhibit tumor xenograft growth of two PDAC cell lines that 
were sensitive to SCH772984 in vitro. We found that SCH772984 treatment of established tumors 
caused tumor regression (HPAC) or impaired progression (HPAF-II) (Figure 2.12A). No weight 
loss was seen, indicating that the treatment was well tolerated (Figure S6A). These anti-tumor 
activities were associated with reductions in pRSK in the tumor tissues (Figure 2.13B, 2.13E and 
2.13F), consistent with ERK inhibition at the tumor sites, and with reduced total protein levels of 
MYC and Aurora B (Figure 2.12B).  We did not observe depleted levels of MYC mRNA, supporting 
a mechanism whereby loss of MYC in vivo was due to protein degradation (Figure 2.12C). 
Furthermore, two in vitro-resistant cell lines were similarly not sensitive to SCH772984 in vivo 
(Figure 2.13C and 2.13D). 
  Since PDAC PDX mouse models may more accurately model drug response in cancer 
patients (Hidalgo et al., 2014), we next evaluated SCH772984 sensitivity in four different serially 
passaged KRAS-mutant PDX tumors surgically implanted into the flanks of nude mice. 
SCH772984 significantly reduced (70-90%) tumor growth in all four PDX models (Figure 2.12D), 
and this was associated with decreases in protein but not RNA levels of MYC and Aurora B 
(Figures 2.12E, 2.12F, 2.13G, and data not shown).  We also observed loss of cyclin B1, cyclin 
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D1, and pRB, but no induction of cleaved caspase-3, suggesting halted cell growth rather than 
induction of apoptosis (Figures 2.12E and 2.13G).  Together with our in vitro observations, these 
results in both cell line- and patient-derived tumor xenografts indicate that loss of MYC and Aurora 
B proteins may be accurate in vivo markers of SCH772984 sensitivity.   
We next expanded our analysis to include an orthotopic xenograft mouse model of PDAC, 
as stromal cells are known barriers to drug delivery/efficacy in the pancreas.  We observed that 
SCH772984 decreased pERK, pRSK, and MYC levels and reduced tumor size (Figures 2.12G, 
2.12H, 2.12I, and 2.13H).  Since we showed previously that Ral inhibition suppressed pancreatic 
tumor growth (Lim et al., 2006), we also tested the combination of SCH772984 with dinaciclib, a 
CDK inhibitor that blocks pancreatic tumor growth by suppressing KRAS-Ral signaling  (Feldmann 
et al., 2011; Feldmann et al., 2010).  This combination resulted in a more significant reduction in 
tumor growth than either treatment alone.   
Finally, because we had observed that the clinical candidate ERK inhibitor BVD-523 also 
synergized with the PI3K inhibitor AZD8186 in vitro, we sought to determine its efficacy in vivo.  
We observed markedly reduced tumor growth with this combination (Figure 2.13I).  Importantly, 
western blot analysis and tumor staining revealed ERK target inhibition, as measured by 
decreases in pERK, pRSK, pS6, and p4E-BP1 levels (Figure 2.13J and 2.13K). Together, our 
data suggest that ERK inhibition alone or in combination with other targeted agents may be 
beneficial for treatment of PDAC patients.  
Identification of Resistance Mechanisms to Short-term SCH772984 Treatment 
To assess the mechanistic basis of de novo resistance (Figure 2.1A), we used two 
strategies.  First, we applied reverse-phase protein array (RPPA)-based pathway activation 
mapping analysis (Liotta et al., 2003) to a panel of sensitive and de novo resistant cell lines to 
measure the basal activation/phosphorylation state of 135 key signaling proteins involved in cell 
proliferation, autophagy, apoptosis, survival, migration and adhesion. We identified a distinct 
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signature that distinguished sensitive versus resistant cell lines (Figure 2.14A). Within this 
signature, there was a significant (p<0.05) activation of the PI3K-AKT-mTOR signaling network, 
with increased phosphorylation/activation of AKT and of multiple AKT substrates (e.g., p27, NF-
κB, as well as mTOR substrates such as 4E-BP1, EIF4G, S6 ribosomal protein) (Figure 2.14A). 
In agreement with our observation that inhibitors of PI3K signaling synergistically enhanced 
SCH772984 inhibitory activity in sensitive cell lines, RPPA pathway mapping analyses identified 
PI3K-AKT-mTOR signaling as a key driver of ERK inhibitor resistance.	
Second, we applied a kinome siRNA library screen to identify genes displaying synthetic 
lethality with SCH772984.  Using two SCH772984-resistant PDAC cell lines (CFPAC-1 and 
SW1990), we performed two independent kinome-wide siRNA screens (711 genes) in the 
absence or presence of SCH772984. Subsequent validation analyses in three PDAC cell lines 
(CFPAC-1, SW1990 and DAN-G) verified 24 genes whose targeting by at least two different 
siRNAs enabled SCH772984 to suppress anchorage-dependent growth in otherwise resistant cell 
lines (Figure 2.14B and 2.14C). Further validation showed that siRNA suppression along with 
SCH772984 treatment decreased cell growth by greater than 70% (Figure 2.14D-G).  We 
identified new genes as well as known modulators of MAPK-inhibitor resistance (Johannessen et 
al., 2010).  These analyses reveal the striking heterogeneity in the signaling mechanisms that can 
drive de novo resistance to ERK inhibition. 
Since the majority of kinases identified in our screen have not been associated previously 
with resistance to RAF or MEK inhibitors, we performed Ingenuity Pathway Analysis on our hits 
to determine their possible relevance to ERK signaling. This analysis identified recognized 
associations with ERK signaling in 13 of the 24 kinases (Figure 2.15). These results indicate that 
multiple and diverse mechanisms will likely drive de novo and/or acquired resistance to ERK 
inhibition. 
To investigate mechanisms of acquired resistance to ERK inhibition, we applied an 
innovative gain-of-function screen (aka Cancer Toolkit, CTK (Martz et al., 2014)) to identify 
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activated signaling components that can cause acquired resistance.  The CTK is a library of 
barcoded expression constructs consisting of key genes in 20 of the oncogenic pathways most 
commonly activated in cancer.  We examined potential mechanisms of acquired resistance to 
both SCH772984 and the clinical candidate BVD-523.  Interestingly, we found that CTK-induced 
acquired resistance to SCH772984 and BVD-523 yielded many overlapping hits, which included 
PI3K, Notch, and p38 signaling cascades (Figure 2.14H-J).  With inhibitors of Notch and p38 
under clinical evaluation, their application together with ERK inhibitors may be tested rapidly to 
determine if these combinations delay onset of acquired resistance.  
DISCUSSION 
Clinical experiences with RAF and MEK inhibitors in BRAF-mutant melanomas emphasize 
that the RAF-MEK-ERK cascade is not a simple linear signaling pathway (Samatar and 
Poulikakos, 2014). Clearly, each level of the cascade is subject to distinct regulatory mechanisms, 
with inhibition at each level leading to distinct compensatory mechanisms and drivers of inhibitor 
resistance. Furthermore, Raf and MEK inhibitors that induce loss of ERK-mediated negative 
feedback mechanisms, leading to increased pathway flux and ERK reactivation (Nissan et al., 
2013) have been largely ineffective in RAS-mutant cancers.  Our recent finding that ~50% of RAS-
mutant human cancer cells are responsive to the ERK-selective inhibitors SCH772984 and BVD-
523 (clinical candidate), despite their resistance to MEK inhibitors (Morris et al., 2013), suggests 
that inhibition of the pathway at the level of ERK may be advantageous (Hatzivassiliou et al., 
2012). 
An unexpected finding from our studies was the different mechanisms of growth 
suppression seen upon short-term (24-72 hr) versus long-term (1-2 weeks) ERK inhibitor 
treatment.  Conventionally, mechanisms of growth suppression by signaling inhibitors are 
characterized by short-term analyses, yet clinical application of such inhibitors involves persistent 
long-term treatment. As with MEK inhibitors (Alagesan et al., 2015), short-term treatment (24-72 
hr) with this ERK inhibitor induced growth suppression that was associated with perturbation of 
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progression through G1 and induction of apoptosis. In contrast, we found that long-term treatment 
(weeks) instead caused a senescence-like growth suppressive phenotype, which was dependent 
on the proteasomal degradation of MYC. Since clinical use of ERK inhibitors will certainly require 
long-term treatment, the induction of this phenotype may be the more clinically relevant 
mechanism of action. There is emerging appreciation that drug-induced senescence may be part 
of an important and effective approach for cancer treatment (Nardella et al., 2011) by rendering 
cancer cells sensitive to cytotoxic drugs. 
Our application of unbiased chemical library screening and phosphoprotein profiling 
independently identified the PI3K-AKT-mTOR pathway as a key mediator of ERK inhibitor 
sensitivity. However, while concurrent treatment with MEK and PI3K inhibitors has recently been 
explored in mouse models of pancreatic cancer, only modest anti-tumor activity was observed 
(Alagesan et al., 2015; Junttila et al., 2015).  Furthermore, clinical trial evaluations of MEK and 
PI3K inhibitor combinations also suggest that normal tissue toxicity may limit this combination 
(Shimizu et al., 2012; Tolcher et al., 2015).  Clinical evaluation of PI3K and ERK inhibitor 
combinations will be needed to determine whether targeting ERK rather than MEK will overcome 
these limitations. 
We found that a significant subset of KRAS-dependent pancreatic cancer cell lines 
exhibited de novo resistance to this ERK inhibitor.  Our RPPA phosphoprotein profiling analyses 
identified a PI3K-AKT-mTOR activation signature that distinguished sensitive versus resistant cell 
lines. Mutations activating the PI3K-PTEN-AKT signaling cascade have been associated with de 
novo resistance to MEK inhibition in RAS-mutant cancers (Wee et al., 2009).  However, most of 
our ERK inhibitor-resistant cell lines did not contain such mutations. Furthermore, concurrent PI3K 
inhibition, which conferred increased growth inhibition in ERK inhibitor-sensitive cells, could not 
overcome ERK inhibitor resistance in the de novo resistant cells.  Thus, increased PI3K signaling 
together with additional mechanisms must drive de novo resistance. 
	 54	
 In support of such additional mechanisms, our kinome siRNA library screen identified a 
striking diversity of protein kinases that, when inactivated, overcame ERK inhibitor resistance.  
Although there was but one overlap in the hits from two full kinome siRNA library screens, 
validation of the combined hits showed that the majority drove resistance in a third cell line. This 
striking heterogeneity is not unexpected in light of the fact that there are numerous alterations in 
non-KRAS genes that are not widely shared among PDAC tumors (Waddell et al., 2015). This 
may be why both ERK-dependent and -independent pathways can overcome KRAS addiction.  
Recent studies identified the transcription factor YAP1 as one mechanism that can overcome loss 
of mutant K-Ras in KRAS-mutant PDAC (Kapoor et al., 2014; Shao et al., 2014).  While these 
studies provided compelling evidence in support of YAP1, additional modulators are likely to be 
revealed.  Future studies will be needed to expand on these observations.   
Importantly, we employed a genetic gain-of-function screen to identify mechanisms of 
acquired resistance to ERK inhibition.  SCH772984 and BVD-523 shared several hits from the 
screen, namely, PI3K, Notch and p38.  None of these has previously been identified as a 
modulator of ERK resistance (Goetz et al., 2014; Vogel et al., 2015).  Together, our results stress 
that many distinct ERK inhibitor-based combinations will be needed for efficacy across different 
KRAS-mutant PDAC populations.  Elucidation of the molecular determinants of ERK inhibitor 
response will be critically needed to accomplish our goal of achieving effective personalized 
medicine for KRAS-mutant PDAC patients.  
MATERIALS AND METHODS 
Cell Lines 
PDAC cell lines were obtained from ATCC and were maintained in Dulbecco’s Modified 
Eagle Medium supplemented with 10% fetal calf serum (FCS) (HPAC, PANC-1, and MIA PaCa-
2), in RPMI 1640 supplemented with 10% FCS (AsPC-1, CFPAC-1, HPAF-II, HuPT3, Panc10.05, 
and SW-1990) or with 15% FCS (Capan-1 and Capan-2). 
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Western Blot Reagents  
Cells were lysed in 10% NP-40 Buffer (1 M Tris pH 7.5, 1 M MgCl2, 5 M NaCl, 10% NP-40, 10% 
glycerol, 0.25% sodium deoxycholate; phosphatase and protease inhibitors) and resolved by 
SDS-PAGE.  To determine the levels of activated proteins, blot analyses were done with phospho-
specific antibodies to AKT(S473), MEK1/2(S217/S221), RSK(T359/S363), and 
ERK1/2(T202/Y204), with antibodies recognizing total AKT, MEK1/2, RSK, and ERK1/2 to control 
for total protein expression (Cell Signaling Technologies). Antibodies to MYC, Aurora B, ubiquitin, 
ETS1, DUSP4, p21/CIP1, and p53 (Cell Signaling Technologies), and to ETS2 and DUSP6 
(Abcam), and to DUSP1 and p16 (Millipore) were used to monitor total protein expression. To 
assess the mechanism of MYC degradation, phospho-specific MYC (T58 or S62) antibodies 
(Abcam) were used.  Antibody to KRAS4B was obtained from Calbiochem. Antibodies for cleaved 
caspase-3 (Cell Signaling Technologies) were used to monitor apoptosis. Antibody for β-actin 
(Sigma AC15) was used to verify equivalent loading of total cellular protein. 
 
Small Molecule Inhibitors 
The ERK1/2-selective inhibitor SCH772984 was synthesized at Merck.  The MEK1/2-
selective inhibitor selumetinib/AZD6244 was provided by G. Johnson (UNC-CH).  The PI3K 
inhibitor AZD8186 was provided by AstraZeneca.  Inhibitors for in vitro studies were dissolved in 
dimethyl sulfoxide (DMSO) to a yield of 10 or 20 mM stock concentrations stored at -20 or -80°C, 
respectively.  
siRNA Transfections 
siRNA silencer select oligonucleotides against scrambled and KRAS sequences were obtained 
from Invitrogen and transfected into cells by using Lipofectamine RNAiMAX, according to the 
manufacturer’s instructions.   
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Retroviral Expression Vector Infections 
The pMSCVpuro retrovirus vector and pMSCVpuro encoding Flag epitope-tagged MYC 
(T58A) were provided by Juan Belmonte (Addgene plasmid 20076) (Aasen et al., 2008), and were 
transiently transfected into 293T cells with a pCL-10A1 packaging system using a calcium chloride 
transfection reagent.  Viral particles were collected and infected as described above for 
lentiviruses. Infection of PDAC cell lines was done in growth media supplemented with 8 g/ml 
polybrene. 
 
Anchorage-Dependent Growth Assays 
To monitor proliferation, cells were plated into 96-well plates at a density of 1 x 103 (MIA 
PaCa-2, PANC-1, HPAC), 2 x 103 (CFPAC-1, SW-1990, HPAF-II, Panc10.05, AsPC-1), or 3 x 103 
(Capan-1) cells per well.  To quantitate cell number, after 4 or 7 days, cells were stained with 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and absorbance was measured 
at 550 nm. We also performed a second proliferation assay to monitor clonogenic growth. Cells 
were plated at the same number of cells per well as for the MTT assay, but in 6-well plates.  After 
7 to 10 days, paraformaldehyde-fixed cells were stained with crystal violet to visualize and 
quantitate colony growth. 
 
Determination of GI50 
To determine the 50% growth inhibitory concentration (GI50), 1-2 x 103 cells were seeded in 96-
well plates and treated with concentrations of SCH772984 or selumetinib from 3.9 nM to 4 µM). 
After 72 hr of treatment, cell proliferation was analyzed with MTT and read at an absorbance of 
550 nm.  GI50 values were calculated with CalcuSyn or CompuSyn software. 
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Cell Cycle Assay 
Cell cycle progression was quantified by flow cytometry as described (Nusse et al., 1990). Cells 
were treated at GI50 for 72 hr and then washed with phosphate-buffered saline (PBS), fixed in 
cold 70% ethanol, and then stained with propidium iodide (PI).  Modfit software was used for 
analyses. 
 
Drug Sensitivity and Resistance Testing (DSRT) Chemical Library Screen 
DSRT was performed on pancreatic cancer cell lines. The compounds were dissolved in 
100% dimethyl sulfoxide (DMSO) and dispensed on tissue culture–treated 384-well plates 
(Corning) using an acoustic liquid handling device, Echo 550 (Labcyte Inc.). The compounds were 
plated in five different concentrations in 10-fold dilutions covering a 10,000-fold concentration 
range relevant for each drug (e.g., 1–10,000 nmol/L). The predrugged plates were kept in 
pressurized StoragePods (Roylan Developments Ltd.) under inert nitrogen gas until needed. The 
compounds were dissolved with 5 μL of culture medium while shaking for 30 min. Twenty μL of 
single-cell suspension (1,000 cells) was transferred to each well using a MultiDrop Combi 
(Thermo Scientific) peristaltic dispenser. The plates were incubated in a humidified environment 
at 37°C and 5% CO2, and after 72 hr cell viability was measured using CellTiter-Glo luminescent 
assay (Promega) with a Molecular Devices Paradigm plate reader according to the 
manufacturer’s instructions. The data were normalized to negative control (DMSO only) and 
positive control wells (containing 100 μmol/L benzethonium chloride, effectively killing all cells).  
Curve fitting and calculations of drug sensitivity scores were performed as previously described 
(Yadav et al., 2014). 
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Senescence-Associated β-Galactosidase Assay 
Cell lines were treated with SCH772984 at GI50 or 2 x GI50 for 7, 10, or 14 days on plastic.  Cells 
were then plated in 12-well plates at a density of 1-5 x 103 cells per well and stained using the 
Senescence β-galactosidase Staining Kit from Cell Signaling Technologies.  Positive cells were 
quantitated after 24 hr staining 
PDAC Cell Line Xenografts 
Female athymic nude mice (nu/nu, 6 to 8 weeks of age, Charles River Laboratories, 
Wilmington, MA) were maintained under pathogen-free conditions in microisolator cages. Animal 
procedures were performed in accordance with the rules set forth in the NIH Guide For The Care 
And Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at Merck. All animals received food and water ad libitum. 
HPAC, HPAF-II, CFPAC-1 and PANC-1 cells (3.5 × 106 in PBS:Matrigel (1:1)) were 
injected s.c. into the right flank region of the mice.  Tumors were allowed to reach 300 to 450 mm3 
before randomization to treatment groups. For continuous dosing studies, SCH772984 was 
administered intraperitoneally (i.p.) at 75 mg or 90 mg per kilogram body weight (mpk) once daily 
(qd) for 14 to 21 days. Mice in vehicle-control arms received 20% (2-hydroxypropyl)-β-cyclodextrin 
(HPBCD) on the same schedules that SCH772984 was administered. Ten mice were in each 
treatment group. Tumor volumes were measured twice weekly using calipers and calculated by 
the formula (length x width x width x 0.5).  Animal body weights were measured on the same days 
twice weekly.  Statistically significant differences between the treatment groups were determined 
by the Student’s t-test and 2-way ANOVA using GraphPad Prism. Six hr after their last dose, mice 
were euthanized by carbon dioxide inhalation.  The tumors were then removed and cut into two 
pieces.  One piece was frozen in liquid nitrogen while the second piece was fixed in 10% formalin 
for future analysis. 
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Patient-derived Subcutaneous Xenograft Studies 
All animal experiments conformed to the guidelines of the Animal Care and Use 
Committee of Johns Hopkins University and animals were maintained in accordance to guidelines 
of the American Association of Laboratory Animal Care. Subcutaneous murine xenografts were 
generated from low-passage patient-derived human pancreatic cancer xenograft (PDX) models 
Panc185 and Panc215, as previously described (Rubio-Viqueira et al., 2006). Xenografts were 
serially transplanted into both flanks of ten male CD1 nu/nu athymic mice each (n = 20 xenograft 
tumors per case). Mice for each model were randomized into two groups of five mice with similar 
average xenograft tumor volumes and assigned to receive treatment with SCH772984 (50 mg/kg 
in 10% (2-hydroxypropyl)-β-cyclodextrin, b.i.d.) or vehicle only (n = 10 xenografts per arm). 
Treatment was initiated when xenografts were 150-250 mm3. After treatment (Panc354, Panc215, 
Panc185, and Panc374) all mice were euthanized and tumor tissues harvested, within 3 hr after 
final drug treatment. Tumors were measured, and half of the tumor tissues were fixed with 10% 
formalin and half of them were frozen for future analysis.  
 
Patient-derived Orthotopic Xenografts 
All animal experiments conformed to the guidelines of the Animal Care and Use 
Committee of Johns Hopkins University and animals were maintained in accordance to guidelines 
of the American Association of Laboratory Animal Care. For orthotopic models, PDX tumors were 
surgically implanted in the pancreata of 40 male CD1 nu/nu athymic mice each.  Tumor growth 
was monitored by ultrasound (Vevo 770); treatment was initiated when orthotopic tumors were 
150-250 mm3. Mice for each model were randomized into 4 treatment groups with similar average 
xenograft tumor volumes and assigned to receive treatment with SCH772984 (25 mg/kg in 10% 
(2-hydroxypropyl)-β-cyclodextrin (HPBCD), i.p. three times per week), dinaciclib (20 mg/kg in 10% 
HPBCD, i.p. twice weekly), a combination of SCH772984 and dinaciclib, or vehicle only (n = 10 
xenografts per arm). After treatment, all mice were euthanized and tumor tissues harvested, within 
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3 hr after final drug treatment. Tumors were measured, and half of the tumor tissues were fixed 
with 10% formalin and half of them were frozen for future analysis.  
 
Reverse-Phase Protein Array (RPPA) 
Cell lysates were prepared in SDS sample buffer and printed in triplicate onto 
nitrocellulose coated slides (Grace Bio-labs, Bend, OR) using an Aushon 2470 arrayer (Aushon 
BioSystems, Billerica, MA). Each array was probed with one primary antibody, subjected to 
extensive pre-validation by single band western blotting and ligand induced activation (for 
phosphoproteins) on an automatic Autostainer (Dako Cytomation, Carpinteria, CA) using the 
Catalyzed Signal Amplification System kit (CSA; Dako Cytomation). Fluorescent detection was 
achieved using the streptavidin-conjugated IRDye680 (LI-COR Biosciences, Lincoln, NE) 
according to the manufacturer’s instructions. The total amount of protein contained in each 
sample was measured by Sypro Ruby Protein Blot Stain (Molecular Probes, Eugene, OR). 
Images were acquired using the PowerScanner (TECAN, Mönnedorf, Switzerland) and spot 
intensity values were quantified using MicroVigene software Version 5.1.0.0 (Vigenetech, 
Carlisle, MA) as previously described (Pin 2014). The quantitative values obtained for each 
analyte were checked for data normalcy, and parametric two-tailed t-test (normally distributed 
data) or non-parametric Wilcoxon rank sum test (non-normally distributed data) was performed to 
identify statistically significant (p<0.05) differences in the basal signaling activation between ERK 
resistant and ERK sensitive cell lines.  Because of data dependency of the kinase-based 
phosphoprotein data, no false discovery rate filtering was applied. Analysis was performed using 
R v2.13.2. GraphPad Prism v5.02 (GraphPad Software) was used to generate data plots. 
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siRNA Library Screening  
Four siRNA sequences for each gene from the Human Validated Kinase V4 siRNA Library 
(Qiagen) were selected for screening and utilized to create nine 384-well assay plates. In addition, 
all assay plates included negative control siRNAs (Non-Silencing, All-Star Non-Silencing, and 
GFP), and two positive control siRNAs for transfection (UBBs1 and All-Star Cell Death Control), 
all of which were purchased from Qiagen. The siRNAs were printed individually into white solid 
384-well plates (1 μl of 0.667 μM siRNA per well for a total of 9 ng siRNA) using a Biomek FX 
(Beckman Coulter). Lipofectamine RNAiMax (Invitrogen) was diluted in serum-free RPMI media 
and 20 μl was transferred into each well of the 384-well plate containing siRNAs using a BIO-TEK 
µFill Microplate Dispenser (final concentration is 40 nl of lipid per well). After an incubation period 
of 30 min at room temperature to allow the siRNA and lipid to form complexes, 750 cells in 20 μl 
volume of cells were added into each well using a µFill. Transfected cells were incubated at 37°C 
for 24 hr prior to the addition of 10 μl per well of varying concentrations of SCH772984 or vehicle 
control (DMSO) for a total assay volume of 50 μl. Cells were then incubated at 37°C for 96 hr post 
drug treatment. Cell viability was measured using the CellTiter-Glo assay (Promega) and an 
Analyst GT Multimode reader (Molecular Devices).  
 
siRNA Library Screening Data Analysis  
The raw luminescence values generated in the primary high-throughput RNAi screen were 
aligned and annotated with their respective gene names. The data were initially subjected to 
quality control evaluation. The overall transfection efficiency of >98%, coefficient of variation (CV) 
<10%, and assay quality measure, Z-Factor >0.9 were achieved, indicating a high-quality screen. 
A nonlinear four-parameter curve was fitted through the 6 doses corresponding to each siRNA 
per gene, using Prism 5.0 (GraphPad). GFP negative control was selected as the reference 
control because it has the most robust, non-toxic consistent fit when compared to the other 
	 62	
negative siRNA controls. The curve fitting resulted in a four-parameter output for each fit, namely 
top, slope, IC50 and bottom. The top of each siRNA curve fit was compared to the corresponding 
GFP top parameter. A ratio was generated, and any siRNA which indicated >20% toxicity was 
flagged and removed from further analysis as being “toxic”. For hit selection, a fold change was 
calculated between the IC50 of each siRNA curve and the corresponding IC50 of the GFP control 
curve. A five-fold cutoff was applied in order to select strong hits. To minimize the off-target effect, 
we set a stringent criteria of at least 2 corresponding siRNAs targeting the same gene to have a 
IC50 fold change of ≥5. Based on this criterion, a final primary screen hit list of 23 genes was 
generated. 
 
Cancer Toolkit (CTK) Screening 
Cancer Tool Kit lentivirus expression vectors were provided by Kris Wood (Duke). Open 
reading frame (ORF)- or shRNA-expressing lentiviruses were produced and added to six-well 
plates in the presence of polybrene (7.5 mg/ml). After virus addition, plates were centrifuged at 
2200 x g for 1 hr at 37°C. Twenty-four hr after infection, puromycin (2 mg/ml) was added for 
selection, and cells were incubated for 48 hr. Cells were then trypsinized, counted, and seeded 
in 96-well plates at 2000 cells per well. Twentyfour hr later, DMSO or concentrated serial dilutions 
of the indicated drugs (in DMSO) were added to cells. The viability was calculated as the 
percentage of control (vehicle-treated uninfected parental cells) after background subtraction with 
a minimum of three replicates for each cell line/ORF (or shRNA)/drug/concentration.  
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Table 2.1. 
 
Table 2.1. Mutant KRAS PDAC cell lines 
 
 
 
 
 
 
 
 
 
 
Table 2.1  Mutant KRAS PDAC cell lines
Cell Line
MIA PaCa-2
HPAF-II
HPAC
Panc10.05
HuP-T3
SW-1990
PANC-1
Capan-1
Capan-2
AsPC-1
CFPAC-1
KRAS
G12C*
G12D/WT
G12D*
G12D*
G12R/WT
G12D*
G12D*
G12V*
G12V/WT
G12D*
G12V/WT
CDKN2A
Del*
R29fs*
Stop/Stop
WT
Del*
Del*
Del*
Del*
WT
WT
WT; methylation
TP53
R248W*
P151S*
WT
I255N/WT
R282W*
WT
R273H*
A159V*
WT
C135fs*35/WT
C242R*
SMAD4
WT
WT
WT
WT
WT
WT
WT
S343ns*
WT
R100T*
Del*
Compiled from COSMIC. *Homozygous; All WT for BRAF, PIK3CA and PTEN; fs, frameshift
mutation; Del, deletion 
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Figure 2.1. 
 
Figure 2.1. PDAC Cell Line Sensitivity to the ERK-Selective Inhibitor SCH772984 Is Not 
Associated with KRAS Dependency. (A) KRAS-mutant PDAC cell lines were maintained on 
plastic in growth medium with DMSO vehicle or SCH772984 (3.9 nM-4 µM). Proliferation was 
monitored by MTT assay to assess growth inhibition after 72 hr treatment.  GI50 values were 
determined using CalcuSyn.  Data are representative of three independent experiments.  Bars 
indicate standard deviation from triplicate samples for each cell line. (B) SCH772984-sensitive 
and -resistant PDAC cell lines were maintained on plastic in growth medium with vehicle or the 
MEK inhibitor selumetinib (3.9 nM-4 µM). MTT assays were performed and GI50 values were 
determined as in (A). (C) Cells were transfected with scrambled (NS) or one of two individual 
siRNAs targeting KRAS (designated KRAS1 or KRAS2) for 48 hr, followed by western blot for 
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total K-Ras4B, ERK1/2 (ERK), AKT1-3 (AKT) and for vinculin to verify equivalent loading of total 
protein. Phospho-specific antibodies were used to monitor phosphorylation and activation of ERK 
(T202/Y204; pERK) and AKT (S473; pAKT). Data are representative of two independent 
experiments. (D) Cells transfected with NS or KRAS siRNAs were monitored for proliferation on 
plastic at 6 days post-transfection by MTT assay. Error bars represent the standard error of the 
mean. Data are representative of three independent experiments.  Asterisks represent statistical 
significance using one-way ANOVA analysis, where * = p < 0.05, ** = p < 0.001, and ns = not 
significant. (E) Cells transfected with NS or KRAS siRNAs were plated at low density and 
clonogenic growth was monitored at 9-12 days post-transfection. Error bars represent standard 
error of the mean. Data are representative of three independent experiments.  Asterisks represent 
statistical significance using one-way ANOVA analysis, where * = p < 0.05, ** = p < 0.001, and ns 
= not significant. 
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Figure 2.2. 
 
Figure 2.2. Related to Figure 2.1. (A) KRAS-mutant PDX cell lines grown on plastic were 
maintained in growth medium supplemented with vehicle (DMSO) or with BVD-523 or 
SCH772984 at concentrations ranging from 3.9 nM to 4 µM. Proliferation was monitored by MTT 
viability assay to assess growth inhibition after 72 hr treatment. GI50 values were determined using 
CompuSyn. All data shown in this figure are representative of three independent experiments. 
Bars indicate standard deviation from triplicate samples for each cell line. (B) KRAS-mutant PDAC 
cell lines grown on plastic were maintained in growth medium supplemented with vehicle (DMSO) 
or with BVD-523 at concentrations ranging from 3.9 nM to 4 µM. Proliferation was monitored by 
MTT viability assay to assess growth inhibition after 72 hr treatment. GI50 values were determined 
using CompuSyn. All data shown in this figure are representative of three independent 
experiments. Bars indicate standard deviation from triplicate samples for each cell line. (C) 
Western blot analysis of ERK activation following treatment with selumetinib (AZD6244) at 75 and 
4800 nM for 72 hr. Blot analysis of β-actin was done to verify equivalent loading of total cellular 
protein. Data shown are representative of three independent experiments. (D) The consequences 
of siRNA KRAS suppression on anchorage-dependent growth was monitored on plastic 7 days 
post-transfection. Error bars represent the standard error of the mean. Asterisks represent 
statistical significance using one-way ANOVA analysis, where * p < .05, ** p < .001, and *** p < 
.0001. (E) The consequences of siRNA KRAS suppression on clonogenic growth with the 
indicated PDAC cell lines was determined by colony formation on plastic 9-12 days post-
transfection. Shown are photomicrographs (scale bar, 100 µm) of representative dishes after 
staining with 2 mg/ml crystal violet after 9-12 days post-siRNA transfection. (F) Western blot 
analysis following shRNA-mediated KRAS knockdown showing the effects on K-Ras4B protein 
expression, phosphorylation status of ERK and AKT, and β-actin as a loading control for total 
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cellular protein. (G) Anchorage-dependent growth assay following shRNA-mediated KRAS 
ablation using one verified KRAS-directed shRNA sequence in a panel of KRAS- mutant PDAC 
cell lines. Anchorage-dependence was measured 4 and 7 days post-selection. Error bars 
represent the standard error of the mean of two independent experiments. Asterisks represent 
statistical significance using a paired t-test analysis, where * p < 0.05, ** p < 0.001, and *** p < 
0.0001. (H) Anchorage-independent growth assay in soft agar following shRNA-mediated KRAS 
ablation using one verified KRAS-directed shRNA sequence (1) in a panel of KRAS- mutant 
PDAC cell lines. Anchorage-independent growth was measured post selection. Cell lines were 
allowed 2-4 weeks of growth. Error bars represent the standard error of the mean of two 
independent experiments. Asterisks represent statistical significance using a paired t-test 
analysis, where * p < 0.05, ** p < 0.001, and *** p < 0.0001. 
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Table 2.2. 
 
Table 2.2. PDX-derived PDAC cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 PDX-derived PDAC cell lines 
Cell Line
Pa02C
Pa03C
Pa04C
Pa14C
Pa01C
Pa16C
Pa18C
KRAS
Q61H*
G12D/WT
G12V*
G12D*
G12D/WT
G12D/WT
G12D/WT
CDKN2A
Del*
WT
Del*
Del*
WT
WT
Del*
TP53
L247P*
L244P*
Del*
Del*
T155P*
I255N
WT
SMAD4
Del*
WT
WT
fs-indel*
Del*
WT
Del*
*Homozygous; fs, frameshift; indel, in frame insertion, deletion, or duplication change affecting 
more than a single codon
SCH772984
sensitive
Y
Y
Y
Y
N
N
N
Tissue of
Origin
Liver metastasis
Liver metastasis
Liver metastasis
Primary tumor
Liver metastasis
Primary tumor
Primary tumor
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Figure 2.3. 
 
Figure 2.3. Short-term SCH772984 Treatment Induces Apoptosis and Altered Cell Cycle 
Progression.  (A) SCH772984-sensitive or -resistant cell lines were treated for 72 hr with DMSO 
vehicle or SCH772984. Non-adherent cells were collected and monitored for apoptosis by 
western blot for cleaved caspase-3. Data are representative of three independent experiments. 
(B) Cells treated as above were stained with propidium iodide followed by flow cytometry. Error 
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bars represent standard error of the mean. Asterisks represent statistical significance using one-
way ANOVA analysis, where * = p < 0.05. (C) Cells treated as above were collected for western 
blot for total cyclin B1, cyclin D1 and p21, and of phosphorylated, inactivated RB (S807/811; pRB). 
Western blot for pERK was done to verify SCH772984 inhibition; β-actin was the loading control.  
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Figure 2.4. 
 
 
Figure 2.4. Related to Figure 2.3. (A) SCH772984 sensitive or resistant cell lines were treated 
with vehicle or the indicated concentrations of SCH772984 for 72 hr and adherent cells were then 
collected for blot analyses to monitor apoptosis by formation of the cleaved activated caspase-3 
fragment. Blot analysis for β-actin was done to verify equivalent loading of total cellular protein. 
Data shown are representative of three independent experiments. (B) SCH772984-sensitive 
PDAC cell lines were maintained on plastic in growth media supplemented with vehicle or a range 
of concentrations from 3.9 nM to 4 µM of the SCH772984 for 24, 72, 120, and 168 hr. MTT assays 
were performed and GI50 values were determined. Error bars represent the standard error of the 
mean of three independent experiments. 
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Figure 2.5  
 
Figure 2.5 SCH772984 Sensitivity Is Associated with Treatment-Induced AKT 
Phosphorylation. (A) Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984, then 
evaluated by western blot with phospho-specific antibodies for RSK (T395/S363; pRSK), MEK1/2 
(S217/221; pMEK), AKT (S473; pAKT), and ERK (T202/Y204; pERK). Total RSK, ERK, AKT, 
MEK and β-actin were also analyzed. Data are representative of three independent experiments. 
(B) Cells were treated as in (A) for 72 hr and evaluated by western blot for DUSP1, DUSP4, 
DUSP6 and β-actin. (C) SCH772984-sensitive (Panc10.05) and -resistant (CFPAC-1) cell lines 
were treated concurrently with selumetinib (5 μM) and either vehicle or the indicated 
concentrations of SCH772984. Phosphorylated and total RSK, MEK, ERK and vinculin were 
evaluated by western blot. (D) Cells were treated as above and collected for western blot for 
pCRAF (S338), pCRAF (S289/296/301), total CRAF and β-actin. (E) Cells were maintained in 
growth medium with vehicle or SCH772984 (3.9 nM-4 mM), with or without the PI3K inhibitor 
AZD8186 (1 µM).  MTT was used to assess growth inhibition after 72 hr.  Data are representative 
of three independent experiments.  Bars indicate standard deviation from triplicate samples for 
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each cell line. (F) Cells were co-treated with SCH772984 and AZD8186.  Western blots were 
performed for pAKT (S473) and total AKT, caspase-3 and β-actin. 
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Figure 2.6. 
 
Figure 2.6 Related to Figure 2.5. (A) Sensitive or resistant cell lines maintained on plastic with 
complete serum-supplemented growth media were treated for 72 hr with vehicle or the indicated 
concentration of SCH772984, then evaluated by blot analysis with phospho-specific antibodies 
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for RSK (T395/S363; pRSK) and ERK. Blot analyses for total RSK, ERK, and β-actin to verify 
equivalent loading of total cellular protein were also done. Data shown are representative of three 
independent experiments. (B) Sensitive or resistant cell lines maintained on plastic with complete 
growth media were treated for 72 hr with vehicle or the indicated concentration of SCH772984, 
then evaluated by blot analysis with phospho-specific antibodies for MEK1/2 and AKT. Blot 
analyses for total AKT and MEK, and for β-actin to verify equivalent loading of total cellular protein 
were also done.  (C) Sensitive or resistant cell lines maintained on plastic with complete growth 
media were treated for 4, 24, and 72 hr with vehicle or the indicated concentration of SCH772984, 
then evaluated by western blot analysis with phospho-specific antibodies for RSK (T395/S363; 
pRSK) and ERK. Blot analyses for total RSK, ERK, and vinculin to verify equivalent loading of 
total cellular protein were also done. Data shown are representative of three independent 
experiments. (D) Sensitive or resistant cell lines maintained on plastic with complete growth media 
were treated for 4, 24, and 72 hr with vehicle or the indicated concentration of SCH772984, then 
evaluated by blot analysis with phospho-specific antibodies for CRAF, MEK1/2 and AKT. Blot 
analyses for total CRAF, AKT and MEK, and for vinculin to verify equivalent loading of total cellular 
protein were also done. (E) Cells were treated as described above (A-D) for 4, 24 and 72 hr and 
then evaluated by blot analyses for DUSP4 and DUSP6 protein levels, with vinculin as the loading 
control. (F) Sensitive or resistant cell lines were co-treated with SCH772984 and AZD8186.  Blot 
analysis was performed for phospho-AKT (S473), caspase-3 and total AKT. β-actin or vinculin 
served as a loading control (LC). (G) Sensitive or resistant cell lines maintained on plastic with 
complete serum-supplemented growth media were treated for 72 hr with vehicle or the indicated 
concentration of SCH772984, then evaluated by blot analysis with phospho-specific antibodies 
for RSK, pRSK, AKT, pAKT, pERK and ERK. Blot analyses for total RSK, ERK, AKT and β-actin 
to verify equivalent loading of total cellular protein were also done. Data shown are representative 
of two independent experiments. (H) Sensitive or resistant cell lines grown on plastic were 
maintained in growth medium supplemented with vehicle or with SCH772984 at concentrations 
ranging from 3.9 nM to 4 µM, with and without the addition of 1 µM AZD8186. Proliferation was 
monitored MTT viability assay to assess growth inhibition after 72 hr treatment. Data shown are 
representative of two independent experiments. (I) MIA PaCa-2 cells were maintained on plastic 
with complete serum-supplemented growth media were treated for 72 hr with vehicle or the 
indicated concentration of BVD-523, then evaluated by blot analysis with phospho-specific 
antibodies for pERK and total antibodies for MYC and ERK. Vinculin was used to verify equivalent 
loading of total cellular protein. (J) MIA PaCa-2 cells were grown on plastic were maintained in 
growth medium supplemented with vehicle or with BVD-523 at concentrations ranging from 100 
nM to 10 µM, with and without the addition of GDC-0941.  Proliferation was monitored by MTT 
viability assay to assess growth inhibition after 72 hr treatment. (K) KP mouse cells were grown 
on plastic were maintained in growth medium supplemented with vehicle or with BVD-523 at 
concentrations ranging from 100 nM to 10 µM, with and without the addition of GDC-0941. 
Proliferation was monitored by MTT viability assay to assess growth inhibition after 72 hr 
treatment. 
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Figure 2.7. 
 
 
Figure 2.7. Distinct Patterns of Drug Synergies in ERK versus MEK Inhibitor Combinations. 
HPAC and Panc10.05 cells were exposed to dose-dependent drug sensitivity testing (DSRT) 
against 309 oncology-related compounds in the presence or absence of the ERK inhibitor 
SCH772984 (2 µM) or the MEK inhibitor AZD6244/selumetinib (1 µM). Cell viability was measured 
using CellTiter-Glo and drug responses were calculated as drug sensitivity scores (DSS). Plotted 
in the heatmap are the deltaDSS values (DSS in the presence of ERK/MEK inhibitor – DSS in the 
absence of overlaid inhibitor) for each condition, where red signifies potential synergies and blue 
indicates negative interactions between the two drugs. Drugs where the deltaDSS remained 
between -5 and 5 for all four conditions were excluded from the heatmap. 
 
 
 
!"
#$
%
!&
'
(
)!
!"
#$
%
!*
&(
)!
!#
+,
-.
/!
&'
(
)
!#
+,
-.
/!
*
&(
)
!"#$%&'()&$*%!
!+&,-.('()&$*%!
!/0#'()&$*%!
!12345567!
!89275::!
!892;5<=!
!>?@45;A!
!BC45=A576A<!
!@DE<;7!
!FE4;;56!
!3)($&.#G#!
!F(H#I&G(%I-I!
!/GI&G(%I-I!
!D-0&I(H)-J!
!"('#$&.#G#!
!2-G*%#'I&K!
!+-)&$#I&G&K!
!B-G(K&G(%I-I!
!L&G%&I&G&K!
!"-$(J&.#G!
!D&GI#,-G&K!
!@4M/"<:<!
!"&N&.-'G&K!
!OP4<</!
!@$-I&G&K!
!QRSTU<!
!D&)(I&G&K!
!3V)('(W*&G#!
!2#J-$#IV-%(G#!
!B'#,G&%()(G#!
!F#IVX)N'#,G&%()(G#!
!O&GK)-%I&G#!
!O&GH'&%I&G#!
!2(H#I-J#)!
!B-I*N&)(G#!
!B-H)&I-J#)!
!O()-%#'I&K!
!B&HI&)&%&K!
!BC45=6Y<:5;!
!?-'-H-I&G&K!
!MF?4A:=75A!
!F&,(%I-*'&G!
!2-%-I&G&K!
!D#'-I&G&K!
!/')(I&G&K!
!"'#I&G(&G!
!1#.&I&G&K!
!8.-I&G&K!
!3-G#'I&G&K!
!2-H($&I&G&K!
!1#$H&I-K&G#!
!3)(.-'-K&G#!
!2-*G('*K&H&G!
!@,-'*K&H&G!
!O-)'*K&H&G!
!F#IV(I'#J-I#!
!>J-)&N)-I&G!
!"8E4AZZ!
!B&$-%#'I&K!
!"'-$#I&G&K!
!+#.-$#I&G&K!
!4<:
!4<5!
!4:!
!5!
!:!
!<5!
!<:!
,#)I-2??
$">+[!8E"[!NA5?6E
"E!Q8MLS[!\283[!
M3L4.-$&)X[!M+2!-G,
-*I(NV-]X!&GV&K&I('%[
/+!$(,*)-I('%
&$$*G($(,*)-I('%
-GI&4$&I(I&H%
B@ZE[!@1C<+[!?+3
.-$&)X!&GV&K&I('%
/1C+!&GV&K&I('%
8GI&$#I-K()&I#!G*H)#(%&,#
-G-)(]%
"(N(!@@!&GV&K&I('%[
-GI&$#I-K()&I#%
F/E!&GV&K&I('%
8924;5<=!Q\B83S
< <5 <55 <555 <5555
5
;:
:5
A:
<55 3(GI'()
R/+E&
RF/E&
H(GH!QGFS
^
0&
-K
&)&
IX
TU<!Q\B83S
< <5 <55 <555 <5555
5
;:
:5
A:
<55 3(GI'()
RF/E&
R/+E&
H(GH!QGFS
^
0&
-K
&)&
IX
2(H#I-J#)!!QB-<5_:S
5_< < <5 <55 <555
5
;:
:5
A:
<55 3(GI'()
R/+E&
RF/E&
H(GH!QGFS
^
0&
-K
&)&
IX
/')(I&G&K!!QB-<5_:S
< <5 <55 <555 <5555
5
;:
:5
A:
<55 3(GI'()
R/+E&
RF/E&
H(GH!QGFS
^
0&
-K
&)&
IX
	 77	
Figure 2.8. 
 
 
Figure 2.8. Long-term SCH772984 Treatment Induces Markers of Senescence and 
Ubiquitination in Sensitive but Not Resistant Cell Lines. (A and B) Cells were treated with 
SCH772984 at GI50 or at 2x GI50 concentrations for 14 days and stained for β-galactosidase. 
Representative images (scale bar, 50 µm) are shown in the left panel, with quantitation in the right 
panel.  Error bars represent standard error of the mean. Data are representative of three 
independent experiments. Asterisks represent statistical significance using one-way ANOVA 
analysis, where * = p < 0.05 and ** = p < 0.001. (C) Cells were treated with SCH772984 for 14 
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days on plastic, followed by western blot for pRB, pRSK and pERK, and for total p16, RSK and 
ERK; β-actin was a loading control. (D and E) Cells were treated with vehicle or SCH772984 for 
7 days, and then immunoblotted for ubiquitin or for β-actin. 
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Figure 2.9. 
 
Figure 2.9. Related to Figure 2.8. (A) Senescence associated β-galactosidase stain of sensitive 
and resistant cell lines after 72 hr of SCH772984 treatment. Error bars represent the standard 
error of the mean for three independent experiments. Asterisks represent statistical significance 
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using one-way ANOVA analysis, where * p < 0.05. (B) Blot analysis of RSK, ERK, and caspase-
3 following 72 hr of SCH772984 treatment. β-actin is a loading control. Data shown are 
representative of three independent experiments. (C) Blot analysis of pRb, p16INK4A, p53, and p21 
following 72 hr of SCH772984 treatment. β-actin is a loading control. Data shown are 
representative of three independent experiments. (D) Blot analysis of Aurora kinase B, MYC, 
ETS1 and total ubiquitin following 72 hr of SCH772984 treatment. β-actin is a loading control. 
Data shown are representative of three independent experiments. (E) Senescence associated β-
galactosidase stain of sensitive and resistant cell lines after 7 days of SCH772984 treatment. 
Error bars represent the standard error of the mean for three independent experiments. Asterisks 
represent statistical significance using one-way ANOVA analysis, where * p < 0.05. (F) Blot 
analysis of Aurora kinase B, MYC, RSK, ERK, p53, and p21 following 7 days of SCH772984 
treatment. β-actin is a loading control. Data shown are representative of three independent 
experiments. (G) Blot analysis of pRB and p16INK4A following 7 days of SCH77984 treatment. Blot 
analysis for β-actin was done to verify equivalent loading of total cellular protein. (H) Blot analysis 
of p53 and p21 following 14 days of SCH77984 treatment. Blot analysis for β-actin was done to 
verify equivalent loading of total cellular protein. (I, J) Sensitive (I) or resistant (J) cell lines 
maintained on plastic were treated with vehicle or the indicated concentration of SCH772984 for 
14 days, and then blotted for ubiquitin or β-actin to verify equivalent loading of total cellular protein. 
(K) Blot analysis of RSK, ERK, p53, p21, pRB, p16INK4A, and total ubiquitin following 14 days of 
300 nM and 600 nM SCH772984 treatment in Panc10.05. β-actin is a loading control for total 
cellular protein. Data shown are representative of three independent experiments. (L) Blot 
analysis of Aurora B, MYC, ETS1 and total ubiquitin following 14 days of 300 nM and 600 nM 
SCH772984 treatment in Panc10.05. β-actin is a loading control. Data shown are representative 
of three independent experiments. (M) Blot analysis of pRSK/RSK, pERK/ERK, pRB, MYC, and 
p16 following 14 days of 600 nM SCH772984 treatment in Pa03C. Blot analysis for vinculin was 
done to verify equivalent loading of total cellular protein. (N) Pa03C cell line was treated with 
SCH772984 at 600 nM for 14 days and then stained for β-galactosidase expression (scale bar, 
100 µm). (O) Schematic of SCH772984 removal assay. (P) β-galactosidase staining of sensitive 
cell lines after 28 days of SCH772984 treatment. Error bars represent the standard error of the 
mean for three independent experiments. Asterisks represent statistical significance using one-
way ANOVA analysis, where * p < 0.05. (Q) β-galactosidase staining of sensitive cell lines after 
14 days of SCH772984 removal. Error bars represent the standard error of the mean for three 
independent experiments. Asterisks represent statistical significance using one-way ANOVA 
analysis, where * p < 0.05. (R) The consequences of SCH772984 removal on anchorage-
dependent growth were monitored on plastic at 1, 3, and 7 days.  Error bars represent the 
standard error of the mean. (S) Blot analysis of Aurora B, MYC, pRB, and p16 following long-term 
treatment with SCH772984. β-actin is a loading control. Data shown are representative of three 
independent experiments. (T) Blot analysis of Aurora B, MYC, pRB, and p16 following removal of 
SCH772984 after long-term treatment with SCH772984. Vinculin is a loading control. Data shown 
are representative of three independent experiments. 
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Figure 2.10. 
 
Figure 2.10. Induction of Senescence Is Dependent on Proteasomal Degradation of cMYC. 
(A) Cells were treated with vehicle or SCH772984 for 7 days, then immunoblotted for Aurora B, 
MYC, ETS1 or ETS2, and β-actin.  Data are representative of three independent experiments. (B) 
Sensitive cell lines were treated with vehicle or the indicated concentrations of SCH772984 for 7 
days, and then co-treated with either vehicle (-) or MG132 (10 μM, +) for an additional 8 hr, 
followed by western blots for Aurora-B, MYC, ETS-1, and ETS-2. β-actin is the loading control. 
(C) Densitometry analysis of MYC protein levels from (B). (D) Sensitive cell lines were treated 
with vehicle or SCH772984 for 7 days, and then immunoblotted with phospho-specific antibodies 
for Myc residues T58 or S62 (pMYC), or for total MYC and β-actin. (E) Cells were treated as in 
(D) and then MG132 (10 µM) was added for 8 hr. (F) Sensitive Panc10.05 cells maintained on 
plastic were treated with either vehicle (-) or SCH772984 (1,000 nM, +) for 7 days, then co-treated 
with either vehicle (-) or MG132 (10 μM, +) for an additional 8 hr. Whole cell lysates (WCL) were 
then subjected to control normal serum (mock) or to anti-MYC immunoprecipitation (IP), resolved 
by SDS-PAGE and then immunoblotted for ubiquitin or for MYC, and for vinculin to verify 
equivalent loading of total cellular protein. (G) Sensitive Panc10.05 and HPAC cells stably 
infected with either the empty pMSCV retrovirus vector (EV) or pMSCV encoding a FLAG epitope-
tagged ubiquitination-deficient MYC T58A mutant were treated with vehicle or SCH772984 for 10 
or 14 days. Western blot was performed to determine levels of Aurora-B, MYC, and FLAG.  
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Asterisk denotes band of interest. β-actin is the loading control. (H) Panc10.05 and HPAC cells 
expressing either EV or MYC T58A were treated with SCH772984 for 10 or 14 days, then stained 
for β-galactosidase. The percentage of β-galactosidase-positive cells was determined. Error bars 
represent standard error of the mean. Asterisks represent statistical significance using an 
unpaired t-test, where ** = p < 0.01 and * = p < 0.05. (I) Images (scale bar, 100 µm) of β-
galactocidase-positive cell staining in Panc10.05 and HPAC cells, stably infected with the empty 
pMSCV puro retrovirus vector (EV) or pMSCV encoding MYC T58A, after 10 or 14 days of 
SCH772984 treatment. 
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Figure 2.11. 
 
 
 
	 84	
Figure 2.11. 
 
Figure 2.11. Related to Figure 2.10. (A) RT-PCR analysis of mRNA levels of AURKB, MYC, 
ETS1, and ETS2. Sensitive and resistant cell lines were treated with SCH772984 for 7 days on 
plastic. Error bars represent the standard error of the mean for three independent experiments. 
(B) Densitometry analysis of ETS1 and ETS2 protein levels from Figure (2.10B). (C) HPAC cells 
maintained on plastic were treated with either vehicle (-) or 300 nM SCH772984 (+) for 7 days, 
and then together with either vehicle (-) or 10 µM MG132 (+) for an additional 8 hr.   Whole cell 
lysates (WCL) were then subjected to control normal serum (mock) or to anti-MYC 
immunoprecipitation (IP), resolved by SDS-PAGE and then blotted for ubiquitin and MYC, and 
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vinculin to verify equivalent loading of total cellular protein. (D) HPAF-II cells maintained on plastic 
were treated as described in panel (C). (E) Blot analysis of MYC phosphorylation and total protein 
expression. Sensitive cell lines were treated with SCH772984 for 14 days.  MYC phosphorylation 
at residues T58 and S62 was determined by phospho-specific antibodies. Blot analysis for β-actin 
was done to verify equivalent loading of total cellular protein. (F) Cells were transfected with 
scrambled (NS) or two individual siRNAs targeting MYC (designated M1 or M2) for 48 hr, followed 
by western blot analysis of total MYC, pRB, p16INK4A, and β-actin to verify equivalent loading of 
total protein. Data shown are representative of three independent experiments. (G) Cells 
transfected with NS or MYC siRNA were plated at low density and clonogenic growth was 
monitored by quantitation of colony formation at 9-12 days post-transfection. Error bars represent 
the standard error of the mean. Data shown are representative of three independent experiments. 
(H) The consequences of siRNA MYC suppression on clonogenic growth of the indicated PDAC 
cell lines was determined by colony formation on plastic 9-12 days post-transfection. Shown are 
photomicrographs (scale bar, 100 µm) of representative dishes after staining with 2 mg/ml crystal 
violet after 9-12 days post-siRNA transfection. (I) Cells treated as in (H). Shown are 
photomicrographs (scale bar, 100 µm) of representative fields after staining withbβ-galactosidase 
after 9-12 days post-siRNA transfection. (J) Sensitive cell lines were treated with 100 g/ml 
cycloheximide (CHX) for 0, 30, 60, and 120 min. Blot analysis depicts endogenous MYC loss as 
a consequence of CHX treatment. β-actin serves as a loading control. (K) Quantitation of blot data 
from (J) for percentage of MYC remaining after CHX treatment. (L) Half-life calculations (min) of 
MYC protein in sensitive cell lines. (M) Blot analysis depicts endogenous MYC loss as a 
consequence of CHX treatment with cells previously treated with SCH772984 at the indicated 
concentrations for 72 h.  β-actin serves as a loading control. (N) Quantitation of blot data from (M) 
for percentage of MYC remaining after CHX treatment in cells previously treated with 
SCH772984. (O) Half-life calculations (min) of MYC protein in SCH772984-treated sensitive cell 
lines. (P) HPAC and HPAF-II cell lines expressing either empty vector (EV), MYC wild-type (WT), 
MYC T58A, MYC (S62A), and MYC (T58A/S62A), were treated with CHX as in (J). Blot analysis 
depicts exogenous MYC loss a consequence of CHX treatment. β-actin serves as a loading 
control. (Q) Quantitation of blot data from (P) for percentage of MYC remaining after CHX 
treatment. (R) Half-life calculations (min) of MYC in HPAC and HPAF-II expressing empty vector 
(EV), MYC WT, MYC T58A, MYC (S62A), and MYC (T58A/S62A). (S) HPAC cell line treated with 
SCH772984 for 24, 48, 72, 96, 120, 144, 168, and 168 hr plus 10 µM MG132. Blot analysis depicts 
endogenous loss of MYC. β-actin serves as a loading control. Graph depicts densitometry of 
percentage MYC remaining. (T) Panc10.05 cell line was treated as in (S). (U) HPAF-II cell line 
was treated as in (S). (V) HPAC cell lines expressing either empty vector (EV), MYC WT, MYC 
T58A, MYC (S62A), and MYC (T58A/S62A) were treated SCH772984 for 72 hr. Western blot 
analysis depicts exogenous MYC loss as a consequence of SCH772984 treatment.  β-actin 
serves as a loading control. (W) Cells treated as in (M) for 7 days. 
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Figure 2.12. 
 
 
Figure 2.12. SCH772984 Inhibition of Tumor Growth Is Associated with Suppression of Myc 
and Aurora B Abundance. (A) HPAC or HPAF-II cells were injected subcutaneously into the 
flanks of nude mice.  Tumors were allowed to reach 300-450 mm3, then mice were treated i.p. 
daily with vehicle (20% hydroxypropyl beta-cyclodextrin or HPBCD) or with SCH772984 at 75 or 
90 mpk for 21 or 14 days, respectively. Error bars represent standard error of the mean (n=10). 
(B) Tumors from mice treated as in (A) were harvested after 21 days and lysates were analyzed 
by blotting for Aurora B and MYC protein. (C) Tumors from mice treated as in (A) were harvested 
after 21 days and analyzed by RT-PCR for AURKB and MYC mRNA. (D) KRAS-mutant pancreatic 
cancer patient-derived xenograft (PDX) cell lines (Panc354, Panc215, Panc185, and Panc374) 
were injected subcutaneously into the flanks of nude mice. Tumors were allowed to reach 200 
mm3, then mice were treated with vehicle (10% HPBCD) or SCH772984 at 50 mpk b.i.d. for 14 
days. Error bars represent standard error of the mean (n=10). Asterisks represent statistical 
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significance using two-way ANOVA, where * = p < 0.05. (E) Panc215 xenograft tumors treated as 
in (B) were harvested after 14 days and lysates were analyzed by blotting for Aurora B, MYC, 
pRB, cyclin B1, cyclin D1, caspase-3 and vinculin. (F) Panc215 xenograft tumors treated as in 
(C) were harvested after 14 days and lysates were analyzed by RT-PCR for AURKB and MYC 
mRNA. (G) Panc253 tumors were orthotopically implanted in nude mice and allowed to grow to a 
mean size of 200 mm3, as measured by ultrasound. Mice were treated i.p. with SCH772984 at 25 
mpk three times per week or with dinaciclib at 20 mpk twice weekly. After 25 days, tumors were 
harvested and weighed. All data represent mean ± SE (n= 7); ***, p < 0.001, each arm versus 
vehicle control. (H) Tumors harvested from mice treated as in (B) were analyzed by western blot 
for phospho-RSK and -ERK, and total RSK, ERK, and MYC. Vinculin is a loading control. (I) 
Images of Panc253 tumors treated as described in (G). 
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Figure 2.13. 
 
Figure 2.13. Related to Figure 2.12. (A) Body weight change after treatment with SCH772984 
in sensitive HPAC and HPAF-II xenografts. (B) Western blot analysis of phosphorylated and total 
RSK and ERK in HPAC and HPAF-II tumors. Tumors were treated for either 18 (HPAF-II) or 21 
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(HPAC) days. (C) CFPAC-1 and PANC-1 cells were injected subcutaneously into the flanks of 
nude mice. Tumors were allowed to reach 300-450 mm3 and mice were then treated i.p. daily with 
vehicle (20% HPBCD) or with SCH772984 at 75 or 90 mpk. Error bars represent the standard 
error of the mean. (D) Body weight change after treatment with SCH772984 in resistant CFPAC-
1 and PANC-1 xenografts. (E) Western blot analysis of phosphorylated and total RSK and ERK 
in Panc215 tumors. Tumors were treated for either with SCH772984 at 50 mpk for 14 days. (F) 
Western blot analysis of phosphorylated and total RSK and ERK in Panc354 tumors. Tumors 
were treated for 14 days either with vehicle control or SCH772984 at 50 mpk. (G) Western blot 
analysis of Aurora B, MYC, pRB, p16, cyclin B1, cyclin D1, and caspase-3 in Panc354 tumors. 
Tumors were treated as in (F). (H) Panc265 tumors were orthotopically implanted in nude mice 
and allowed to grow to a mean size of 200 mm3, as measured by ultrasound. Mice were treated 
i.p. with SCH772984 at 25 mpk three times per week or with dinaciclib at 20 mpk twice weekly. 
After 25 days, tumors were harvested and weighed. All data represent mean ± SE (n= 7); ***, p < 
0.001, each arm versus vehicle control. (I) KP mouse cells were injected subcutaneously into the 
flanks of C57BL/6J mice.  Mice received vehicle (0.5% methylcellulose /0.2% Tween-20 and 1% 
carboxymethyl-cellulose), 50 mg/kg GDC-0941 daily, 100 mg/kg BVD-523 BID, or 50 mg/kg GDC-
0941 daily plus 100 mg/kg BVD-523 twice daily, orally for 14 days. Data are presented as mean 
± SEM. (J) Western blot analysis of pRSK, pERK/total ERK, pS6/total S6, pAKT/total AKT, and 
p4E-BP1/total 4E-BP1 in KP cells. β-actin serves as a loading control (K) Immunohistochemical 
staining of pERK (rabbit polycolonal antibody) in KP xenografts from mice after 2 hr of oral gavage 
with 2 mg BVD-523, 1 mg GDC-0941 and combination of BVD-523 and GDC-0941 (1 mg BVD-
523 + 0.5 mg GDC-0941).  
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Figure 2.14. 
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Figure 2.14. 
 
Figure 2.14. Related to Figure 2.15. (A) PI3K-AKT-mTOR network (top) activation signature in 
SCH772984-treated established and PDX PDAC cell lines.  Scatter plots (bottom) are shown for 
each network component that was significantly elevated in ERK inhibitor-resistant lines compared 
to ERK sensitive lines. (B) List of genes whose knockdown in resistant PDAC cell lines by at least 
two independent siRNAs caused a 5-fold increase in sensitivity to the ERK-inhibitor SCH772984. 
(C) Venn diagram displaying overlapping hits among ERK inhibitor resistant cell lines. (D) 
CFPAC-1 cells were transfected with siRNA targeting green fluorescent protein (GFP) or RAF-1, 
then exposed to varying concentrations of SCH772984 for 72 hr.  CompuSyn software was used 
to generate GI50 values.  Western blot analysis of RAF-1 and vinculin (total cellular protein loading 
control) after siRNA knockdown. (E) Cells were treated as in (D) with siRNA targeting GFP or 
COT/TPL2. CompuSyn Software was used to generate GI50 values. Western blot analysis of 
COT/TPL2 (encoded by MAP3K8) and vinculin (total cellular protein loading control) after siRNA 
knockdown. (F) Cells were treated as in (D) with siRNA targeting GFP or protein kinase eta 
(PRKCH). CompuSyn software was used to generate GI50 values. Western blot analysis of 
PRKCH and vinculin (total cellular protein loading control) after siRNA knockdown. (G) Cells were 
treated as in (D) with siRNA targeting GFP or CK2α. CompuSyn Software was used to generate 
GI50 values. Western blot analysis of CKα (encoded by CSNK2A1) and vinculin (total cellular 
protein loading control) after siRNA knockdown. (H) and (I) Pa14C cells were transduced with 
individual lentiviral constructs and cultured in the presence of vehicle or either SCH772984 or 
BVD-0523.  Bars show the fold increase in sensitivity relative to vehicle-treated samples. 
Transparent blue shading marks threshold fold enrichment score of 1.0. (J) Common hits between 
SCH772984 and BVD-523.  
 
	 92	
Figure 2.15. 
 
Figure 2.15. Identification of Protein Kinases That Regulate Resistance of PDAC Cell Lines 
to SCH772984. Pathway analysis based on Ingenuity Pathway Knowledge Base. The highest 
scoring networks (Post-translational Modification, Cell Morphology, Cellular Assembly and 
Organization; score 29, p-values < 0.05) were obtained from the proteins identified in our kinome-
wide siRNA SCH772984 resistance screen. A black solid line represents a direct relationship 
between two nodes. A dotted line represents an indirect interaction between two nodes. Shaded 
nodes are the genes identified in our screen. 
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CHAPTER 3: DISCUSSION 
 The use of targeted small molecule inhibitors has greatly impacted the treatment of human 
diseases, from cancer to genetic disorders.  Inhibitors, such as imatinib (Gleevec) have proven to 
be curative, while others, vemurafinib (Zelboraf) for example, have generated new fields of study.  
Unlike genetic tools, such as siRNA, shRNA, or CRISPR/Cas9, inhibitors have both significantly 
impacted our understanding of the complexities of signaling networks and provided a therapeutic 
benefit for patients.  Having said that, there are several current studies evaluating use of siRNA 
as a therapy, however, that therapeutic option is far from the clinic. 
 The use of small-molecule inhibitors has revealed many complexities associated with 
signal transduction networks, yet there are still many unanswered questions.  Today, generating 
protein kinase inhibitors is commonplace; however, not all proteins are as easily targeted.   
GTPases and transcription factors, for example, remain elusive, though there has been an 
intensive effort to develop direct small molecule inhibitors for each.  Ras (GTPase) and Myc 
(transcription factor) proteins represent the two most frequently mutated oncogenes in cancer, 
yet they cannot be directly targeted (Yokota et al., 1986).  To that end, genetic manipulation 
remains the best option to investigate the regulation and function of such proteins.  Using a 
combination of inhibitors and genetic manipulations has significantly enhanced our current 
understanding of signal transduction in mutant RAS driven cancers.  Since we cannot directly 
inhibit mutant RAS, indirect inhibition remains the best available option.  Targeting effector 
cascades associated with mutant RAS dependency are likely the best therapeutic option for 
disruption of mutant RAS signaling.  
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 Chapter II assessed the effectiveness of ERK inhibition in mutant KRAS cancers.    In my 
studies, we identified a bi-modal action of the ERK inhibitor SCH772984 where short and long-
term treatment resulted in differential consequences.  Current inhibitor studies generally focus on 
the effects of short-term treatment, from 24-72 h, however patient treatments are rarely, if ever, 
that acute.  Our studies suggest that the long-term phenotype is likely the more relevant for patient 
treatment.  Furthermore, we identified novel mechanisms of resistance to ERK inhibition that will 
likely drive future combination treatments in PDAC.   In this chapter, I will consider how these 
observations as well as others can guide future investigations.  
 
3.1 Mutant RAS Dependency 
It has been well established that KRAS is the most frequently mutated oncogene in cancer, 
however, whether mutant KRAS cancers are still dependent on the continued expression of 
mutant KRAS for growth/survival remains partially unanswered.  We know from mouse models 
that mutant RAS is essential for initiation, progression, and maintenance (Chin et al., 1999; 
Johnson et al., 2001; Lim and Counter, 2005).  However, recent studies have suggested that not 
all mutant KRAS cancers are dependent on the continued expression of mutant KRAS (Singh et 
al., 2009).  Most of these analyses have been carried out using an in vitro tumor cell line culture 
model.   
Our tumor cell line data, in both established and PDX tumor cell lines, suggests that all 
mutant KRAS tumor cell lines are dependent on the continued expression of mutant KRAS for 
growth.  Additionally, we have even expanded our findings to include mutant NRAS and HRAS 
cancers.  Consistent with our observations in mutant KRAS tumor cell lines, we find that 
suppression of either oncogenic NRAS or HRAS in tumor cell lines containing the respective 
mutation results in reduced growth (data not shown).  We have reproducibly demonstrated this 
observation using both siRNA and shRNA knockdown of mutant KRAS.  Importantly, we observed 
that the degree of sensitivity to loss of mutant KRAS varies between tumor cell lines.  Furthermore, 
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sensitivity is also dependent on the effectiveness of knockdown, as might be expected.  When 
mutant KRAS is depleted by greater than 90%, the growth rate is markedly reduced.   
Defining the notion of sensitivity (or dependence) is a key aspect to understanding what 
seems to be contradictory data.   Our lab has defined sensitivity as growth in either an in vitro 
anchorage-dependent (2D) or -independent (3D) assay.  Historically, anchorage-independent 
growth assays have been the gold standard for predicting in vivo efficacy, meaning that 
observations made under anchorage-independent conditions are more likely to be recapitulated 
in an in vivo system.  We, as well as others, find that mutant KRAS dependency is equally 
observable under both 2D and 3D systems (Bryant et al., 2014;Commisso et al., 2013). 
However, several other prominent studies have defined sensitivity as induction of 
apoptosis/survival.  In these studies, several groups were able to distinguish between tumor cell 
lines that were dependent on the continued expression of mutant KRAS, and ones that were 
independent (Fujita-Sato et al., 2015; Singh et al., 2009). Cleaved-caspase-3 and PARP, both 
markers indicative of apoptosis, were enhanced when mutant KRAS tumor cells lines were 
depleted of K-Ras in one such study.  In further support of this observation, ectopic expression of 
mutant KRAS was able to partially reverse the apoptotic phenotype suggesting that it was an on-
target effect.   
How can these seemingly opposing observations coexist, without disproving either each 
other?  In studies where mutant KRAS depletion results in an apoptotic phenotype, there is still a 
population of attached cells.  Though the attached cells are not replicating as fast as the control, 
they are still viable as marked by uptake of crystal violet or MTT.  After time, this population can 
be characterized by markedly reduced cellular growth compared to the control.  In our studies, 
we find this same cellular population when mutant KRAS is depleted.  Consistent with this 
observation, other studies have found that depletion of K-Ras in mutant KRAS cells can result in 
cell cycle arrest as measured by Propidium Iodine (P.I.) staining (Halilovic et al., 2010).  Together, 
both the reduced growth and apoptotic observations suggest that the total population of cells is 
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quite heterogenous.  This notion partially reconciles the multiple phenotypes observed with the 
depletion of mutant KRAS.  However, which phenotype is most relevant remains unresolved. 
Future Studies 
To effectively investigate the oncogene dependency question, I would propose to use both 
in vitro and in vivo techniques.  First, I would make a confetti (or rainbow) cell line expressing 
GFP, RFP, CFP, and YFP fluorophores in order to follow individual clones.  We would first take a 
Ras mutant tumor cell line (either established and PDX) and isolate a large number of individual 
clones.  These clones would then be infected with a different fluorophore; once infected I would 
set up various mixtures of clones from that cell line.  Then we would deplete Ras, using a 
combination of siRNA, shRNA, and CRISPR/Cas9 techniques, from these cells to determine the 
effect on each subpopulation.  I would measure the effects using standard growth assays in 
combination with a fluorescent scope to follow each subpopulation.  Additionally, we would use 
flow cytommetry to isolate each subpopulation.  After isolation of each subpopulation, markers of 
apoptosis and cell cycle would be analyzed.  After demonstrating proof of concept, I would expand 
this system to include many mutant RAS (K-Ras, H-Ras, and N-Ras) tumor cell lines. 
Furthermore, we would characterize these populations by investigating changes in effector 
usage after Ras depletion.  We would accomplish this using reverse-phase protein array (RPPA), 
which would determine changes in phosphorylated and total proteins downstream of mutant RAS 
in each subpopulation.  In Chapter II, we effectively used RPPA to distinguish between basal 
signaling in ERK inhibitor sensitive and resistant cell lines.  From there, we were able to reveal a 
ERK inhibitor resistance signature that was associated with PI3K signaling in the ERK inhibitor 
resistant cell lines.  This was an interesting and somewhat confusing observation, in that we also 
observed that PI3K signaling was important in ERK inhibitor sensitive cell lines.  The difference 
being that basal PI3K signaling was elevated in resistant cell lines even before the ERK inhibitor 
was administered.  This was in opposition to ERK inhibitor sensitive cell lines, which only activated 
PI3K signaling after ERK inhibitor treatment.  Collectively, those observations suggest that 
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activating PI3K signaling has the same effect in both cell line conditions, where in sensitive cell 
lines it prevents apoptosis in a portion of the cellular population and in resistant cell lines it 
prevents apoptosis in the entire cellular population. 
In combination with RPPA, we would use MiB M/S (multiplex-inhibitor beads), as this 
would tell us about the changes in kinase activity.  I have already generated data demonstrating 
that loss of K-Ras leads to marked changes in total tyrosine, threonine, and serine 
phosphorylation levels (Fig. 3.1A-C).  Based on our initial observations, it is likely that RPPA and 
MiB M/S analysis will reveal promising hits.  These observations would then be validated in our 
cell lines.  To delve deeper into the heterogeneous nature of tumor cell lines, we would use 
capillary electrophoresis to separate and quantify nonphosphorylated and phosphorylated 
proteins in single cells (Proctor et al., 2014).  Additionally, we would perform RNAseq on each 
subpopulation as well as RNAseq on several single cells from each subpopulation in Ras depleted 
cells (Bose et al., 2015).  We would also perform whole genome sequencing in the same manner 
as above.  Together, these data would give us a vast understanding of the genomic landscape of 
Ras dependency.  
While unraveling the genomic landscape associated with Ras dependency is important, 
the methodology behind the experimental design is equally as important.  Molecular signaling is 
a dynamic process that brings together numerous protein networks that are constantly modulated.  
Generally, assessing changes in genomic landscapes are investigated at single time points.  
Experiments of this nature are really snapshots of molecular signaling.  What is becoming ever 
more clear is that signaling networks have a propensity to rewire upon perturbations, in 
sometimes unexpected manners.  Given that observation, we would investigate Ras depletion at 
various time points using all the methods mentioned above.  This would give us a partial 
understanding of the dynamics that characterize Ras dependency.  
Next, we would expand our anaylsis’ to include dependency on other known oncogenes 
in Ras related pathways, such as Myc, B-Raf, and PI3K.  After compiling all the data, we would 
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be in a position to address questions of similarities and distinctions between various oncogene 
addictions and the complexities that drive them.  As the data are generated we will need to use 
bioinformatics and computational analysis to build/design a platform to organize the data in a 
meaningful way.   From there we would take a systems biology approach to design software, 
through a collaboration, that could predict vulnerabilities in oncogene addiction.  After a prediction 
has been made, we would validate the observation in tumor cell lines.  Our system would then be 
expanded to include additional oncogenes and tumor suppressors in pathways unrelated to 
mutant RAS function.   
To support our in vitro efforts, we would develop a confetti mouse model, which marks 
stem cells in the pancreas (Snippert et al., 2010).  Then we would cross this mouse to the KPC 
mouse model (Hingorani et al., 2005).  Once tumors have formed, I would deliver siRNA, targeting 
mutant KRAS (Pecot et al., 2014; Yuan et al., 2014).  Then we would collect tumor tissue from 
the animals using surgical techniques at various time points, where only a portion of the tumor 
was collected, while the rest remained unaltered.  That tissue would be subjected to the same 
genomic analysis mentioned above (RPPA, RNAseq, DNAseq, etc).  After demonstrating success 
in this initial model, we would cross other mutant RAS GEMM mouse models to our confetti 
mouse.  From there we would create another database chronicling the dynamic changes 
associated with mutant RAS oncogene addiction in vivo. 
  Our major goal with these studies would be to identify commonalities in oncogene 
addiction between tumor cell lines and mouse models.  We would hypothesize that these 
commonalities might represent novel vulnerabilities, which might result in new therapies for 
mutant RAS cancers.  This is a key point as mutant RAS, currently, is not targetable.  Therefore, 
it is imperative that we find other potential targets.  Determining the underlying mechanisms of 
oncogene addiction will help to identify these potential targets. 
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3.2 ERK inhibitors in mutant Ras cancer 
It was not until recently that ERK inhibitors started to gain traction as a potential alternative 
to either Raf or MEK inhibition (Nissan et al., 2013).  Numerous studies have identified reactivation 
of ERK as a common mechanism of resistance to Raf and MEK inhibition suggesting that direct 
targeting of ERK could be a superior approach (Hatzivassiliou et al., 2010; Johannessen et al., 
2010; Poulikakos et al., 2010). Furthermore, several other ERK inhibitors, in addition to 
SCH772984, have been rigorously tested in pre-clinical models and show efficacy, with some 
making it to the clinic (Infante et al, 2015, J Clin Oncol 33; abstract 2506, Hatzivassiliou et al., 
2012; Herrero et al., 2015; Morris et al., 2013).   
Future Studies 
Currently, there are a number of ERK inhibitors under development.  Our first 
investigations would involve characterizing/comparing the different ERK inhibitors and 
determining the mechanisms of action of each both in vitro and in vivo.  In Chapter II, we 
investigated the mechanism of action and signaling changes associate with BVD-523, as it is 
already in the clinic for AML (Acute Myelogenous Luekemia and Myelodysplastic Syndromes 
(clinicaltrials.gov), and will likely be moving to the clinic for pancreatic cancer.  Interestingly, we 
found that SCH772984 and BVD-523 have a similar profile of sensitivity in mutant KRAS cell lines, 
meaning that cell lines that are sensitive to SCH772984 are also sensitive to BVD-0523.  
Furthermore, the SCH772984 resistant cell lines are also resistant to BVD-0523.  To date, the 
most significant difference between SCH772984 and BVD-523 seems to be potency, where 
SCH772984 sensitive cell lines have a significantly lower GI50.  Though there is a difference in 
potency, the is resulting phenotypes associated with each inhibitor seem to comparable in short-
term studies.  These observations are consistent with the manner in which the inhibitor works.  
SCH772984 is both an allosteric and ATP-competitive inhibitor, while BVD-523 is an ATP-
competitive inhibitor.  Moving forward, a proteomics approach will be employed to help distinguish 
between BVD-523 sensitive and resistance cell lines, as this inhibitor is moving into in clinical 
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trials.  Furthermore, it would be important to know whether BVD-523 has a bi-modal action similar 
to that of SCH772984.  Finally, BVD-523 long-term treatment phenotypes will need to be 
evaluated. 
Importantly, our in vivo studies were performed in the absence of gemcitabine, the current 
standard of care for PDAC.  It would be necessary to perform a combination treatment with ERK 
inhibitor plus gemcitabine, though our in vitro data suggest that ERK inhibition might not synergize 
with gemcitabine treatment.  This experiment is important to conduct because it is unlikely that 
ERK inhibitor would be given to patients as a stand alone drug.  Furthermore, there are two other 
cytotoxic regimens that have demonstrated promise for the treatment of PDAC, nab-paclitaxel 
and FOLFORINOX.  Future experiments might include combining ERK inhibition with either of 
these two treatment options.  Though toxicities will likely be a hurdle to their success and 
implementation. 
Another difficulty associated with PDAC treatment regimens involves delivery.  Even if 
there was a miracle drug for PDAC, there would still be the obstacle of getting the drug to the 
desired tissue.  PDAC is characterized by a dense stroma, which reduces the likelihood of any 
treatment reaching the pancreas.  Given this observation, it is likely that ERK inhibitors will run 
into the same difficulties.  Currently, there are a number of methods under evaluation to solve this 
problem (Yu et al., 2010).  Carbon nanotubes and nanoparticles are two promising directions for 
addressing the delivery issue; therefore, I would collaborate with a chemistry lab with expertise in 
nano-style delivery to optimize the conditions necessary for transport of ERK inhibitor.  This 
serves an additional purpose in that not all tissue and cells would be exposed to ERK inhibition, 
as would be the case if ERK was administered directly.  This is an significant point, as the ERK 
inhibitors block wild-type proteins and numerous cell types use ERK signaling to mediate growth.  
Using a nano-style delivery system might reduce ERK inhibitor toxicities. 
Another interesting direction would be to assess the efficacy of ERK inhibition in other 
mutant RAS cancers.  Our lab already has promising preliminary data in mutant KRAS lung cancer 
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and mutant NRAS melanoma (data not shown).  There are a number of mutant RAS cancers to 
chose from, we would likely start with lung and colon cancer as they are among the top causes 
of cancer related deaths in the United States and they possess a high frequency of KRAS 
mutations.  We would investigate the same ERK inhibitor phenotypes as we observed in PDAC.  
Then we would expand our studies to include mutant HRAS and NRAS cancers. 
A key observation from our studies was the bi-modal action of ERK inhibition.  When 
performing inhibitor studies, many within the field stick to short time points to determine sensitivity 
and target inhibition, favoring investigations at 24 h and/or earlier.  However, in patients, drugs 
are never prescribed for that length of time.  In our studies, we found distinct mechanisms of 
action between short- and long-term treatments.  It is unlikely this observation is specific to ERK 
inhibition, however studies with other inhibitors have not included long-term treatment.  Generally, 
the only long-term studies performed with inhibitors tend to involve the unraveling of potential 
resistance mechanisms.  This is unlike our studies, where we observe distinct mechanisms of 
action after short- and long-term ERK inhibitor treatment.  Based on our observations, future 
inhibitor studies should be expanded to include longer treatment regiments.  Our studies also 
raise a key question as to which phenotype is most relevant for the treatment of a potential patient: 
apoptosis (short-term) or cell cycle arrest/senescence (long-term) in a tumor cell line model?  Our 
in vivo observations suggest that the later phenotype (long-term treatment) is more relevant.  
While we were unable to observe senescence in vivo, there was a pronounced cell cycle defect 
that was marked by reductions in pRB and cyclin B1 and D1.  Consistent with our in vitro studies, 
we did not observe any changes in apoptosis (short-term phenotype) after extended treatment. 
Interestingly, we noticed that treatment with SCH772984 (short and long-term) in mutant 
KRAS tumor cell lines resulted in widespread protein ubiquitination.  To our knowledge, this is the 
first reported instance where MAPK inhibition has been linked to widespread protein 
ubiquitination.  While, I was able to identify and link the degradation of Myc to senescence 
associated beta-galactosidase staining, there were still a number of proteins that were 
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independently degraded.  It would be interesting to unravel the mechanisms that govern the 
stability of ERK substrates.  In order to determine the identity of those proteins, we would use 
Mass Spectrometry (MS) analysis.   
In parallel we would deplete mutant KRAS from tumor cell lines to look for a similar 
degradation pattern.  We would then extend these analyses to include genetic and 
pharmacological inhibition of other components of the MAPK pathway (Raf and MEK), as well as 
components from other pathways such as PI3K or RalA/B.  This would add a level of specificity 
in terms of effectors modulating this phenotype.  If widespread ubiquitination seems to rely heavily 
on the Raf-MEK-ERK MAPK signaling cascade, it would be interesting to investigate the other 
MAPK (p38 and JNK) signaling cascades.  Once proteins have been identified and validated, we 
would investigate degradation mechanisms in proteins where none have been previously 
determined.   
In support of a degradation phenotype, our lab has preliminary data showing that 
SCH772984 treatment results in degradation of Ets-1 and Ets-2 (also discussed in Chapter II).  
We have data showing that Ets-1 is directly ubiquitinated after treatment (Fig 3.2A-B).  However, 
the mechanism, which allows for Ets protein degradation has not been determined.  We would 
start investigations with a combination of tandem mass spectrometry (MS/MS) and scan site to 
identify possible phosphorylation sites and protein binding motifs.  From there we would make 
mutants and use the Global Protein Stability (GPS) and Quantitative Ubiquitylation Interrogation 
(QUAINT) platforms assess the stability of our Ets-1 mutants (Emanuele et al., 2011; Kim et al., 
2011).  A similar methodology would be employed with other identified proteins.  
 Finally, we would investigate why subsets of proteins are degraded after inhibition of Ras 
signaling.  We would start investigations with whether mutant HRAS, KRAS, and NRAS yield a 
similar degradation pattern with different perturbations, both figenetic and pharmacologic.  
Perhaps specific patterns of protein degradation could be linked to the numerous cancer 
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phenotypes associated with Ras dependency.  This could reveal novel unknown dependencies 
necessary for Ras proteins. 
 
3.3 Ras effectors and ERK inhibition 
 Ras is thought to regulate at least 11-catalytically distinct effectors.  Of those 11 effectors, 
4 of them have been directly linked to mutant RAS oncogensis (Raf, PI3K, Tiam1, and RalGEF).  
All four of these effector signaling cascades have targetable kinases, some of which already have 
potent inhibitors specifically targeting them.  Since mutant RAS has been shown to signal through 
multiple effectors, it is likely that collectively blocking effectors will yield more promising results.  
In Chapter II, we performed a drug sensitivity screen (DSS) where we combined over 500 
inhibitors with the SCH772984 ERK inhibitor in two sensitive cell lines.  Interestingly, we identified 
a number of combinations, including multiple Ras effector targeting strategies. 
Future Studies 
 While, we have already addressed the significance of combination treatments with PI3K 
inhibition and ERK inhibition, we have only preliminarily investigated combination treatments with 
the other lesser studied Ras effectors.  Tiam1 and RalGEF are the lesser studied effectors 
because they are not mutated in cancers, though they have both been shown to be critical for 
mutant RAS oncogenesis.  Though, Tiam1 and RalGEF are not themselves targetable, there are 
targetable kinases in their downstream cascades.  Downstream of Tiam1 are the PAK kinases 
and downstream of RalGEF is TBK1, both which are important for PDAC oncogenesis (data not 
shown).  The DSS screen we performed did not contain inhibitors targeting either Tiam1 or 
RalGEF, therefore, I would propose to gather validated TBK1/PLD and PAK/JNK inhibitors to 
assess the significance of RalGEF and Tiam1 inhibition in combination with ERK inhibition in vitro.  
If these experiments yielded promising hits, we would move to an in vivo model of PDAC.  Finally, 
we would expand these observations to other mutant RAS cancers. 
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3.4 ERK inhibitors in Myc amplified cancers 
 Alterations in Myc are found in nearly 20% of cancers, which makes Myc the second most 
commonly altered oncogene behind Ras (Nilsson and Cleveland, 2003).  Like mutant RAS 
oncogenes, Myc oncogenes are also considered to be undruggable.  Direct targeting of 
transcription factors is not a viable option, currently; therefore, indirect targeting remains the best 
method. While we have yet to determine changes in Myc targeted gene expression in relation to 
Myc protein stability in our cell lines, we do know from our data and others that Myc half-life is 
significantly enhanced in mutant KRAS cells compared to what has been reported for normal cells 
(Sears et al., 2000).  In tumor cells, Myc is known to accumulate in promoter regions of active 
genes and causes transcriptional amplification (Lin et al., 2015).   We also know that ERK is a 
well-established modulator of Myc stability (Farrell and Sears, 2014), data from our lab shows 
that depletion of ERK with siRNA leads to reduction of total Myc protein levels and a growth defect 
(Figure 3.3A-B).  Furthermore, in Chapter II we observed that ERK inhibition leads to reduction of 
total Myc protein level, both endogenous and exogenous.  Therefore, I would hypothesize that 
Myc amplification driven cancers might be sensitive to ERK inhibition. 
Future Studies 
To test this hypothesis, I would focus on cancers with Myc amplifications.  Based on 
publicly data available from cbioportal (www.cbioportal.org), there are several cancers that 
exhibit amplified Myc. Ovarian cancer is characterized by ~43% alteration frequency, which is 
twice as frequent as the next Myc amplified cancer in the sample set used (Figure 3.4).  I would 
employ similar assays as those mentioned in Chapter II to determine a sensitivity profile to ERK 
inhibition.  From there, we would delve into the mechanism and determination of Myc protein 
stability/half-life.  Should ERK inhibition prove to beneficial for ovarian cancer, we would expand 
our studies to include other cancers and move into Myc amplification driven mouse models, of 
which there are several (Morton and Sansom, 2013).  
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3.5 Resistance mechanisms for ERK inhibition in mutant RAS cancer 
 Targeted therapy and resistance mechanisms, in today’s climate, go hand-in-hand, as 
there are few curative drugs on the market.  Consequently, understanding and predicting rewiring 
of signaling networks has become a large focus of pre-clinical and clinical inhibitor evaluations.  
There are two types of resistance, innate and acquired.  Both instances have been intensively 
studied in recent years.  In our studies, we have attempted to identify and understand both innate 
and acquired resistance mechanisms to ERK inhibition. 
 
3.5.1 Acquired Resistance Mechanisms 
Since we observed a cytostatic response to inhibition with SCH772984 induction of 
senescence, we sought to identify combinations that would turn our cytostatic effect to a cytotoxic 
effect.  We observed a number of combinations that made SCH772984 toxic, as measured by a 
reduction in growth.  A significant number of hits from our SCH772984 drug sensitivity screen 
were members of the PI3K-AKT-mTOR signaling cascade.  We found that co-treatment with PI3K 
(AZD8186) and SCH772984 resulted in enhanced apoptosis.  Additionally, we found co-treatment 
with an AKT (AZD5363) inhibitor and SCH772984 synergized (Fig 3.5).   This observation is not 
as surprising considering there have been a number of studies involving MEK inhibition in 
combination with PI3K or mTOR inhibition (Engelman et al., 2008; Faber et al., 2009; Liu and 
Xing, 2008; Sos et al., 2009; Yu et al., 2008).  Furthermore, there is data suggesting that PI3K 
can mediate resistance to MEK inhibitors in mutant KRAS cancers (Wee et al., 2009).  There 
are/have been a number of clinical trials featuring MEK and PI3K combination treatments, which 
have demonstrated efficacy, at the expense of greater toxicity than inhibition of either pathway 
alone (Shimizu et al., 2012). It is likely that co-treatment with an ERK inhibitor plus a PI3K inhibitor 
in patients will have similar toxicity issues. 
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Future Studies 
Outside of PI3K-AKT-mTOR signaling toxicities, we identified a number of interesting 
combination treatments with SCH772984.  For example, we observed a novel synergy with 
chloroquine.  This observation was reproducible in a number of cell lines suggesting it could be a 
widespread vulnerability.  This is an interesting finding, as it has been well established by 
Kimmelman and colleagues that PDAC, a mutant KRAS cancer, is dependent on autophagy for 
tumor growth (Yang et al., 2011).  Furthermore, there are a number of other mutant RAS cancers 
that are at least partially dependent on autophagy, which enhances its attractiveness as a target.  
The next direction for these studies would be to use a mouse model (KPC, orthotopic xenograft, 
etc) to determine the efficacy of co-treatment with chloroquine and SCH772984.  Should the study 
yield promising results, the combination would be taken to clinical trials for patients with mutant 
KRAS cancers.  Another direction would be to determine whether either mutant HRAS or NRAS 
are dependent on autophagy, as this combination could be expanded for the treatment of other 
mutant RAS cancers.   
Long-term inhibitor treatment is a common method for identifying acquired resistance 
mechanisms.  Surprisingly, we were unable to identify resistant clones to SCH772984 treatment 
in sensitive cell lines after months of treatment.  We observed that long-term treatment resulted 
in a senescence-like phenotype, marked by beta-galactosidase staining, loss of pRB levels and 
increased p16 levels.  However, the beta-galactosidase stained cells did not represent the entire 
population of treated cells.  When we removed the inhibitor after long-term treatment, we 
observed a outgrowth of cells; however, this outgrowth grew slower than the vehicle control 
population.  Additionally, a significant portion of the population remained senescent as marked by 
beta-galactosidase staining, loss of pRB levels and increased p16 levels.  Based on our data it 
seems that long-term ERK inhibition with SCH772984 induces either senescence or quiescence.  
Unfortunately, there are not decisive markers to discern quiescence, which make it difficult to 
isolate that population.  However, I would hypothesize that the quiescent cell population is the 
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outgrowth population seen after removal of SCH772984.  Moving forward, it would interesting to 
develop a live cell senescence maker that could be used to distinguish between senescent and 
quiescent cell populations. 
Though we did not observe significant outgrowth after prolonged treatment in sensitive 
cell lines, this does not mean that SCH772984 will be immune to acquired mechanisms of 
resistance.  If anything, recent history has shown us that perturbing signaling networks, especially 
with small molecule inhibitors, invariably results in kinome reprogramming.  To address this 
concern, we turned to Wood and colleagues, as they have developed a platform that allows for 
the identification of acquired resistance mechanisms (Martz et al., 2014; Winter et al., 2014).   
In Chapter II, we identified several acquired mechanisms of resistance for both 
SCH772984 and BVD-0523.  Using both inhibitors, we have implicated PI3K, Notch, p38, and 
Hippo signaling pathways as potential acquired mechanisms of resistance in our studies.  While 
this platform is somewhat artificial, there is evidence (direct and indirect) that ERK interacts with 
the implicated pathways (Bose et al., 2015; Izrailit et al., 2013; Lin et al., 2015; Mendoza et al., 
2011).  However, p38, PI3K, Notch, and Hippo signaling have already been implicated with Raf 
and MEK as mechanisms of resistance (Lin et al., 2015; Martz et al., 2014; Rudalska et al., 2014; 
Wee et al., 2009).  Of these pathways, Notch, PI3K, and p38 are targetable with small molecule 
inhibitors.  We have previously shown that PI3K and AKT combinations with SCH772984 have 
displayed synergy.  Consistent with previous observations, we also find that co-treatment with 
SCH772984 and SB203580 (tool p38 compound) synergizes in KRAS mutant cell lines (Fig 3.6).  
Future studies would entail determining the mechanism by which PI3K, Notch, p38, and Hippo 
signaling determines ERK inhibitor resistance. 
3.5.2 De Novo Resistance Mechanisms 
 We observed that a portion of mutant KRAS cell lines were innately resistant to 
SCH772984 and BVD-523.  Therefore, we performed a siRNA kinome library screen to identify 
targeted mechanisms of innate resistance.  From our screen we found a number of novel kinases 
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that have not been linked to MAPK inhibitor resistance.  Additionally, we identified several kinases 
that are known mechanisms of resistance to Raf and MEK inhibition, which provide some 
validation that our screen yielded real hits.  Next, we plan to determine how our identified hits 
modulate SCH772984 sensitivity.  
Future Studies 
In Chapter II, we identified PRKCH (protein kinase eta) as a potential modulator of ERK 
inhibitor sensitivity.  This hit is interesting as it was also validated in a separate screen using the 
Raf inhibitor, vemurafinib.  Collectively, the data suggests that PRKCH might be acting as 
modulator of Raf-MEK-ERK signaling pathway.  Future studies would entail designing a specific 
drug for a novel interacting kinase, like PRKCH, and then testing a combination treatment in vivo 
with ERK-inhibitor resistant cell lines. 
 
3.6 Inhibitor Dosing 
 Regimented inhibitor dosing is an important feature of patient treatment.  How often, what 
time of day, and how many days in a row should a drug be taken?  These are all extremely 
important questions that, as molecular biologists, many us fail to incorporate into our studies.  
More importantly, how should we design regimens when combining inhibitors?   In this section I 
will discuss use of circadian rhythm and dosing schedules to as tools to yield optimal inhibitor 
regimens.  Circadian clock (rhythm) research is gaining traction in small molecule inhibitor studies 
seeing as most organisms from single cells to humans follow some sort of circadian rhythm.  Most 
cellular processes are somehow connected to a circadian rhythm, from cell cycle progression to 
changes in gene expression.  Signal transduction is no exception as there are numerous studies 
highlighting this observation (Zhang et al., 2014).  This becomes important when considering 
dosing strategies for small molecule inhibitors.  We want to treat patients at the best time to get 
an optimal outcome.   
 
	 113	
Future Studies 
ERK kinase activity has known circadian oscillation patterns, where ERK activity peaks 
during the middle of the light cycle (Eckel-Mahan et al., 2008; Fu and Lee, 2003).  Using this 
observation, we would design future studies to determine when ERK is most active in mutant RAS 
tumors using an in vivo system.  Given the previous result, we would design a regimen that best 
blocks ERK signaling at its activity climax using an in vivo system.  Should this method yield 
significant improvements in tumor reduction, we would move to human patients to determine to 
determine ERK activity climaxes.  While determining climaxes in ERK kinase output would be 
difficult in solid tumors, hematopoietic cancers (Leukemias, etc), driven by amplified MYC, would 
be an ideal system as attaining multiple patient samples would be feasible.   
Furthermore, other Ras effectors are likely to have circadian rhythms which may or may 
not differ from ERK.  Identifying circadian rhythms of these effectors and designing regimens to 
take advantage of the point at which activity is highest would be an important future direction.  
Given sufficient supporting data, we could also set up regimens where we treat with one inhibitor 
for a selected time and then treated with another inhibitor for a selected time (alternate dosing).  
This might allow for combination treatments (ie PI3Ki and MEKi) that otherwise would be too toxic 
if given at the same time for extended periods.  Finally, regimen design is not only relevant for 
ERK inhibitor studies, but can be expanded to any targeted molecule in any cancer. 
 
3.7 Concluding Remarks 
While targeted small molecule inhibitors have expanded our understanding of many 
signaling cascades and how they are intertwined, there are still many limitations to their 
effectiveness as therapeutic treatments.  Very few targeted inhibitors actually target an altered 
protein (ie a mutated kinase), most of them target a wild-type protein.  Targeting an unaltered 
protein is very similar to using a chemotherapy reagent in sense that the inhibitor is blocking its 
given target in a number of tissues, which could result in toxicities and reduced potency for the 
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target tissue.  Though targeting specific alterations has proven successful, there are still 
limitations, namely induction of resistance mechanisms that limit inhibitor efficacy. Resistance 
mechanisms also occur when using inhibitors that block wild-type proteins limiting their 
therapeutic value.  Furthermore, both types of inhibitors rarely become successful clinical 
standards.  So many inhibitors enter the clinic and fail to improve patient outcome, which most 
attribute to poor preclinical investigation.  I tend to agree with this point of view, we need to 
implement more standardized and rigorous preclinical experimentation and evaluation before 
proceeding to the clinic with small molecule inhibitors. 
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Figure 3.1. 
 
Figure 3.1. KRAS stable knockdown leads to changes in phospho-tyrosine, threonine, and 
serine. (A) Western blot analysis following shRNA-mediated KRAS knockdown showing the 
effects on K-Ras protein expression in PANC-1 and CFPAC-1. (B and C) Cells were treated as in 
(A). Western blot analysis of phospho-tyrosine, threonine, and serine in CFPAC-1 (B) and PANC-
1 (C) cell lines. 
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Figure 3.2. 
 
Figure 3.2. ERK-inhibitor treatment in PDAC cell lines causes widespread ubiquitination. 
(A) Sensitive and resistant cell lines maintained on plastic were treated with vehicle or the 
indicated concentration of SCH772984 for 72 h, and then blotted for ubiquitin or β-actin to verify 
equivalent loading of total cellular protein (B) Panc10.05 cells maintained on plastic were treated 
with either vehicle (-) or 1000 nM SCH772984 (+) for 72 h, and then together with either vehicle 
(-) or 10 µM MG132 (+) for an additional 8 hr.   Whole cell lysates (WCL) were then subjected to 
control normal serum (mock) or to anti-Ets-1 immunoprecipitation (IP), resolved by SDS-PAGE 
and then blotted for ubiquitin and Ets-1. 
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Figure 3.3 
 
Figure 3.3. ERK siRNA silencing in Pa14C cell line. (A) Pa14C anchorage-dependent growth 
is reduced following siRNA-mediated ERK1/2. Anchorage-dependent growth was measured by 
MTT 4 days post-selection. (B) Myc protein is reduced with ERK1/2 suppression. Western blot 
analysis following siRNA-mediated ERK1/2 knockdown for total ERK, Myc and vinculin to verify 
equivalent total cellular protein. 
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Figure 3.4 
 
Figure 3.4. MYC amplification in cancer. MYC amplification data compiled from 
www.cbioportal.org. 
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Figure 3.5. 
 
Figure 3.5. SCH772984 combination treatment with AZD5363 (AKT inhibitor). Combination 
treatment with SCH772984 and AZD5363 (AKTi) reduces GI50 in SCH772984 sensitive but not 
resistant cell lines. KRAS-mutant PDX cell lines grown on plastic were maintained in growth 
medium supplemented with vehicle (DMSO), SCH772984, or SCH772984 + .5 μM AZD5363 
(AKTi) at concentrations ranging from 7.8 nM to 4 µM. Proliferation was monitored by MTT viability 
assay to assess growth inhibition after 72 h treatment.  GI50 values were determined using 
CompuSyn. 
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Figure 3.6. 
 
 
 
Figure 3.6. SCH772984 combination treatment with SB203580 (p38 inhibitor). (A) 
Combination treatment with SCH772984 and SB203580 (p38i) reduces GI50 in SCH772984 
sensitive but not resistant cell lines. KRAS-mutant PDX cell lines grown on plastic were 
maintained in growth medium supplemented with vehicle (DMSO), SCH772984, or SCH772984 
+ 1 μM SB203580 (p38i) at concentrations ranging from 7.8 nM to 4 µM.  Proliferation was 
monitored by MTT viability assay to assess growth inhibition after 72 h treatment. GI50 values 
were determined using CompuSyn. (B) p38-related pathway alterations. 
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